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ABSTRACT
Complex cancer phenotypes are defined by their aggressive nature and 
lack of known or accessible therapeutic targets. My dissertation focuses on the 
use of a personalized medicine approach for the identification of novel therapies 
against two complex cancer phenotypes: Basal-like/Claudin-low breast cancer 
and RAS-active nonsmall cell lung cancer.
RAS-active cancer is characterized by the activation of the complex 
signaling network of RAS, which lacks effective therapeutics capable of inhibiting 
the RAS protein itself or the overall pathway. Further complicating treatment is 
the ability of the RAS pathway to be activated independent of the presence of an 
activating mutation in the RAS protein. To broadly characterize pathway activation 
independent of RAS protein mutation, I used a gene-expression-based biomarker for 
RAS network activity in nonsmall cell lung cancer (NSCLC) cell lines, and identified 
RAS activation in both RAS-mutant and wild-type lines. I then screened for drugs 
whose efficacy significantly correlated to RAS network activity and showed that 
EGFR and MEK co-inhibition is an effective treatment personalized against RAS-
active NSCLC. Finally, I demonstrated that EGFR and MEK co-inhibition induced 
apoptosis and blocked both EGFR-RAS-RAF-MEK-ERK and EGFR-PI3K-AKT-
RPS6 nodes simultaneously in RAS-active, but not RAS-inactive NSCLC.
Secondly, I identified a novel compound effective against Basal-like and 
Claudin-low breast cancer (BL-CL). BL-CL is a molecular subtype of breast cancer 
characterized by an aggressive, recurrent and nonluminal nature, epitomized by 
the lack of known therapeutic targets and poor patient prognosis. Using high-
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throughput screening of a marine invertebrate compound library and sequential 
purification of crude fractions, I identified a previously uncharacterized sulfated 
sterol, Topsentinol L Trisulfate (TLT), purified from a marine sponge, and showed 
that it inhibits AMPK and CHK1 but activates p38. Furthermore, I indentified the 
potential use of known AMPK and CHK1 inhibitors, alone or in combination, as an 
effective therapy against BL-CL. Lastly, sensitivity to TLT was projected against 
various human tumors by generating a gene-expression signature that predicted 
breast and bladder cancer as the cancer types most receptive to TLT therapy.
This work describes the identification of novel treatments personalized 
against BL-CL and RAS-active NSCLC, providing a framework for future pre-
clinical studies.
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My dissertation work investigates the use of personalized medicine in 
the treatment of complex cancer phenotypes. I identify two separate therapies 
personalized against RAS-active nonsmall cell lung cancer and Basal-like/
Claudin-low breast cancer. As such, my dissertation necessitates an introduction 
to personalized medicine and its application in cancer therapy and research. 
Afterwards, I introduce the first complex phenotype addressed in my dissertation, 
RAS-active NSCLC, by discussing lung cancer epidemiology and subtypes, while 
linking the RAS pathway to the complicated pathology and treatment difficulty. Lastly, 
I provide the necessary background on Basal-like and Claudin-low breast cancer 
(BL-CL), the second complex cancer phenotype addressed in my dissertation work. 
I provide the reader with the necessary information on breast cancer epidemiology, 
the different subtypes of the cancer, and a section focusing on BL-CL, as well as 
the proteins and pathways targeted and discussed in Chapter 3. The following 
introduction provides the reader with a framework in which to discuss the necessity 
of novel therapeutic treatment against these cancer phenotypes. This facilitates a 
transition to the importance of personalized medical approaches in cancer drug 
discovery and the findings in Chapters 2 and 3, highlighting the purpose of my 
dissertation work. 
1.2  Personalized Medicine in Cancer
Personalized medicine is a vague term that has been subjected to an 
evolving definition with the changing landscape of clinical practice and research 
[1]. The United States National Institutes of Health (NIH), as well as the Food and 
Drug Administration (FDA) view it as the capacity to use the genetic or genomic 
profile of an individual to guide medical decisions in regards to the prevention, 
diagnosis, and treatment of diseases [2]. However, it is becoming readily apparent 
3that personalized medicine is not exclusively attributed to patient individuality. 
Instead, personalized medicine refers to the idea that molecular information 
optimizes the accuracy with which patients are categorized and treated [3]. It 
describes the medical method of classifying individuals into subpopulations based 
on patient similarities in susceptibility to a particular disease or response to a 
particular treatment. Therefore, the impact of personalized medicine depends on 
molecular biomarkers that classify patients to such subpopulation [1-4]. Thus, it can 
be argued that personalized medicine is in fact a misnomer. Genome or precision 
medicine, are two terms that encompass the current practice of incorporating 
genomic information to guide precise medical intervention [3,4]. 
The ultimate goal of personalized medicine is to provide the most effective 
treatment to the right person at the right time, based on molecular assessment of 
guidance towards precise treatment strategy [1-4]. This is particularly important in 
the treatment of cancer, due to the highly heterogeneous and genomically diverse 
nature of the disease that leads to cancer-distinct differences in clinical behavior 
and treatment response [5-8]. Central to incorporating personalized medicine in 
oncology is the acceptance of cancer as a collective phenotypic consequence of 
somatically acquired genetic, genomic and epigenetic modifications. Fortunately, 
with the collaborative consortiums like The Cancer Genome Atlas (TCGA) leading 
the cataloguing process of cancer genomic alternations in patient samples, it 
has become a feasible option [9,10]. It is expected that the generation of such 
comprehensive catalogs of somatic alterations and changes in epigenetic and 
transcriptional states in cancer genomes will improve our capacity to tailor and 
guide the development of therapeutics against the proper patient subpopulation. 
The incorporation of personalized medicine in cancer can no longer be considered 
a fantasy. It is now a realistic option for cancer therapy [2,3,8,10]. Work documented 
in this dissertation explores the personalization of novel compounds and clinically-
4available drugs against particular molecular subtypes of breast and lung cancer. 
Such work would not have been possible without the advent of cancer genomics. 
1.2.1  Cancer Genomics: The Guide for Personalized Medicine
The fundamental role of the genome in cancer development and progression 
first became apparent in the studies performed by David von Hansemann and 
Theodor Boveri. In the late nineteenth and early twentieth centuries, they 
discovered that dividing cancer cells showed peculiar chromosomal aberrations. 
This finding culminated in the proposal that cancer is a result of aberrant clones 
of cells, caused by abnormalities of hereditary material. Further studies identified 
DNA as the molecular substrate of inheritance, leading to the seminal discovery of 
the genomic nature of cancer [11]. However, due to the inherent genomic diversity 
of cancer, the changes involved in the molecular landscape of the disease are 
variable and numerous. Therefore, a systematic approach to catalogue such 
changes in the genome of the cancer cell was required to provide a more detailed 
understanding of the molecular nature of cancer [12].
With the availability of the human genome sequence, the field of cancer 
genomics emerged to investigate large-scale molecular differences between 
normal and cancer cells [12]. Cancer genomics involves the systematic analysis 
of the cancer cell genome with the purpose of describing recurrent aberrations in 
specific cancer types on a genetic or pathway level [9,10,12]. Such studies are 
required to address the molecular heterogeneity arising within histology-specified 
cancer types that add further complexity to the observed differences in clinical 
behavior and treatment response.  More importantly, the successful incorporation of 
personalized medicine to cancer therapy predicated the identification of molecular 
biomarkers that classify tumors based on their ability to respond to a particular 
treatment. Therefore, knowledge of the molecular profile of cancer is necessary to 
5understand cancer behavior and guide selection of therapy for the patient [8,10,12]. 
This is possible through the use of cancer genomics.
Cancer genomics describes the molecular landscape of tumors. This 
information can then be incorporated into personalized medical approaches 
to identify molecular changes that can predict patient outcome, and provide 
information on treatment sensitivity. Chapter 2 and 3 describes the utilization of 
cancer genomics to classify breast and nonsmall cell lung cancer (NSCLC) into 
molecular subtypes, with the purpose of identifying personalized treatment options. 
Cancer genomics has been successfully integrated in various personalized medical 
approaches in the context of cancer prevention, treatment optimization, and patient 
prognosis prediction, as described in the next section. 
1.2.2  Personalized Medicine Approaches in Cancer
Genomics permitted access into the molecular profiles of cancer that 
contribute to the heterogeneity inherent in the disease. This laid the foundation for 
the investigation and exploitation of molecular weaknesses in cancer. Moreover, 
since cancer genomics was readily available, personalized investigation was 
possible through molecular biomarkers [8,13]. Personalized medicine in cancer has 
been used to tailor treatment strategies according to individual genetic, genomic 
or proteomic tumor profiles. This is accomplished using a molecular biomarker 
that identifies a particular patient population or a tumor phenotype responsive to 
a specific treatment [2,8]. Indeed, the effectiveness of this approach is apparent 
in the clinical success of trastuzumab, a direct HER2 inhibitor in the form of a 
monoclonal antibody, and erlotinib, a small molecule inhibitor of EGFR. The success 
of trastuzumab and erlotonib was achieved as a result of tailoring the therapeutics 
to patients whose tumors expressed the respective molecular biomarkers of HER2 
overexpression or an EGFR activating mutation. These molecular biomarkers 
6effectively guided targeted therapy by identifying the subpopulation of cancer 
patients responsive to the treatment [8,14,15]. Furthermore, biomarkers have 
also been used to identify patient populations and tumor phenotypes resistant 
to a particular treatment. For example, colorectal cancer patients suffering from 
a tumor with an activating KRAS mutation exhibit resistance to EGFR inhibition 
therapy [16]. This methodical, molecular-guided personalized cancer therapy is in 
stark contrast to the historical approach of chemotherapy implementation, whereby 
universally toxic agents were used in various combinations to identify the optimal 
treatment [17]. Personalized cancer therapy provides a methodical strategy to 
identify key molecular biomarkers and link them to the optimal treatment regimen. 
Personalized medicine in cancer is also used preventatively, as a method to 
forecast disease risk prior to the appearance of clinical symptoms. This is possible 
through the identification of oncogenes that increase the risk of cancer occurrence 
and applying the proper tests to screen for them in the clinic. The clinical value of 
BRCA1 and BRCA2 tests and their importance as genetic guides towards cancer 
prevention highlight the significance of this aspect of personalized medicine [2,18]. 
Indeed, the greatest risk factor for both breast and ovarian cancer is the inheritance 
of a mutation in either of the breast cancer susceptibility genes BRCA1, BRCA2 or 
both [19]. Women carrying such mutations have a collective lifetime risk of invasive 
breast cancer (up to 70 years of age) of 55-85% and of invasive epithelial ovarian 
cancer of 15-65%. For these women, prophylactic bilateral total mastectomy 
reduces the incidence and risk of breast cancer associated with these mutations 
significantly [20]. However, BRCA1/2 mutations are found in only a small fraction 
(5–10%) of all breast cancers [21].  Therefore, the ability to assess the population 
for these mutations is crucial in order to recommend and tailor such a highly morbid 
procedure as a total mastectomy to the most beneficial group. In this light, the 
ability to personalize cancer prevention interventions is essential. 
7Personalized medicine is also capable of predicting patient prognosis, cancer 
recurrence and treatment outcomes based on molecular tumor profiles [2,22,23]. 
Indeed, one such example is the incorporation of Oncotype DX, a clinically-available 
multigene diagnostic with prognostic and predictive significance. Oncotype DX is a 
multiplex PCR-based assay that analyzes the expression of 21 genes and quantifies 
the probability of cancer recurrence (prognostic significance) and assesses the 
likely benefit of particular chemotherapeutic interventions (predictive significance). 
This diagnostic is tailored to women with hormone receptor positive, lymph node 
negative early stage breast cancer (stages I and II) [23,24]. Through the use of this 
diagnostic test, a personalized assessment of the probability of cancer recurrence 
and potential benefit from chemotherapy is possible. 
Furthermore, another clinically-available test, Mammaprint, assess tumors 
molecularly to provide a personalized prognosis of breast tumor metastasis. 
Mammaprint is a genomic diagnostic test that examines the expression of 70 genes 
using microarray analysis. It has been shown to be a successful prognostic test, 
independent of conventional pathological and clinical markers such as tumor size 
and hormone/HER2 receptor status. It is currently used in the clinic to personalize 
assessment of potential distant metastases in lymph node negative breast cancer 
patients of all ages with tumors small than 5 cm and independent of hormone 
receptor status [6,22,24].
Through the incorporation of cancer genomics, personalized medicine has 
been able to change the landscape of cancer prevention, therapy and research. 
As such, the goal of my dissertation is to incorporate cancer genomics and 
personalized medicine approaches to identify treatments for complex cancer 
phenotypes. A complex cancer phenotype is defined here as an aggressive subtype 
of cancer that is characterized by deregulated signaling in unknown oncogenic 
pathways or known complicated networks that lack available therapeutic targets. 
8In this dissertation, I address two such cancers, RAS-driven nonsmall cell lung 
cancer, with its aberrant signaling in the complex branching RAS pathway, and 
Basal-like/Claudin-low breast cancer, which lacks an identified driver oncogenic 
signaling pathway. The next section will provide background information on the 
former complex cancer phenotype, laying the foundation for the work described in 
Chapter 2 that identifies a novel personalized treatment strategy effective against 
the disease.
1.3  RAS-active Nonsmall Cell Lung Cancer
Lung cancer is the leading neoplasm in incidence and mortality worldwide. 
Every year, more patients die of lung cancer than breast, colorectal and prostate 
cancers combined [25]. Approximately 85% of all lung cancers are caused by 
the carcinogens found in tobacco smoke, with the remainder 15% of lung cancer 
cases occurring in lifetime “never smokers” (those who have smoked less than 100 
cigarettes in their lifetime) [26].  In the US, an estimated 224,210 cases of lung 
cancer are expected in 2014.  Lung cancer is responsible for more deaths than 
any other type of cancer in both men and women. An estimated 159,260 deaths 
that account for roughly 27% of all cancer mortality are expected to occur in 2014. 
The 5-year survival rate of lung cancer has not improved significantly since 1975, 
going up from 12% in 1975 to 18% in 2009 [27], highlighting the desperate need 
for novel therapeutics that can treat lung cancer. 
Lung cancer occurs in two general types, nonsmall-cell lung cancer 
(NSCLC) and small-cell lung cancer (SCLC), making up 85% and 15% of all cases, 
respectively [28]. Three separate subtypes exist within NSCLC: adenocarcinoma, 
squamous cell carcinoma, and large cell carcinoma, comprising 40%, 30% and 
15% of all lung cancer cases, respectively [29]. Smoking is associated with causing 
all major histological types of lung cancer, although the connection is stronger for 
9SCLC and squamous cell carcinoma. In comparison, adenocarcinoma is the most 
common form of lung cancer to occur in never smokers [30,31]. Adenocarcinoma 
tumors have glandular histology and arise in more distal airways, expressing genes 
consistent with their origin in the distal lung. Squamous cell carcinoma tumors 
occur in more proximal airways and are associated with chronic inflammation. This 
subtype is characterized by squamous differentiation, similar to the pseudostratified 
columnar epithelium that lines the trachea and upper airways where these tumors 
form. Lastly, large cell carcinomas are part of a NSCLC subtype that is diagnosed 
by exclusion. This occurs when tumor cells do not display morphological features 
diagnostic of adenocarcinoma, squamous cell carcinoma or SCLC. It is uncertain 
whether large cell carcinomas are genetically distinct from adenocarcinoma or 
squamous cell carcinoma. These tumors tend to be large, partially necrotic and 
composed of undifferentiated cells [32,33]. 
Adding further complexity to NSCLC are the vast molecular differences 
observed among these diverse types and subtypes of lung cancer [32,33]. Genomic 
studies have revealed the molecular landscape of lung cancer and described 
the numerous somatic alterations observed in NSCLC. These modifications 
encompass protein kinases, epigenome modulators, transcription and splicing 
factors, as well as cellular immunity genes. Among the various altered genes 
in NSCLC with relevant preclinical and clinical evidence identified from patient 
tumours is KRAS, a member of the highly oncogenic RAS protein family [32,34]. 
KRAS mutations are found in 17% of all lung cancer cases [35,36]. The survival 
rate for KRAS-positive lung cancer patients is even worse than the other lung 
cancer patients [37]. KRAS mutations occur in 25% of all NSCLC, but are evidently 
rare in SCLC [26]. Furthermore, RAS can be activated without the acquisition of an 
activating mutation [38]. Therefore, it is necessary to accurately classify the lung 
cancers with activated RAS independent of mutation status. In the work described 
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in this dissertation, RAS-active NSCLC is characterized genomically, with the use 
of a RAS gene-expression signature that classifies RAS activation based on global 
pathway activity and transcription. RAS-active NSCLC is defined as a molecular 
subtype of NSCLC characterized by an activated RAS pathway, independent of 
RAS mutation status and NSCLC histological subtypes (adenocarcinoma, large 
cell carcinoma, squamous cell carcinoma). In the following section, I provide an 
elaboration on the RAS pathway, and its role in carcinogenesis and NSCLC to 
present the reader with the required background knowledge on the importance of 
this pathway.  
1.3.1  The RAS Pathway
RAS proteins are key regulators of cell growth and differentiation, with crucial 
roles in the development and maintenance of tumors. In humans, four different 
RAS proteins exist: HRAS, NRAS, KRAS-4A, and KRAS-4B, with the latter two 
being alternative splice variants of the KRAS gene [36,39]. The protein products 
of these genes are widely expressed, with KRAS in particular being expressed 
in almost all cell types. The KRAS gene is found mutated frequently in particular 
forms of cancer, such as pancreatic, colon and lung carcinomas, the latter of which 
is of significance for the body of work described in this dissertation. Mutated NRAS 
on the other hand is often found in melanomas and some leukemias, while mutated 
HRAS is less frequent but observed in bladder, breast, and thyroid carcinomas 
[39,40]. Knockdown studies have indicated that singular or combinatorial inhibition 
of HRAS and NRAS do not severely hinder normal development in mice, whereas 
KRAS is essential [41]. 
While some differences exist in the roles and functions of the proteins, 
HRAS, NRAS and KRAS are highly homologous GTPases, sharing 90% amino 
acid identity and localizing to the cytosolic part of the plasma membrane where they 
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cycle through “on” (GTP-bound) and “off” (GDP-bound) states [42]. The prominent 
structural differences between these RAS proteins occur in the short hypervariable 
region immediately before the C-terminus [39]. However, they share similar RAS 
GTPase characterstics. Purified RAS possesses a low level of intrinsic GTPase 
activity in vitro [42], highlighting the inefficiency of RAS as a GTPase working alone. 
In the cell, RAS is aided by GTPase activating proteins (GAPs) which catalyze the 
GTP to GDP exchange and guanine exchange factors (GEFs), which catalyze 
GDP to GTP exchange [35,36,38,42-45].  The most common mutations that target 
the RAS genes occur in codons 12, 13 and 61; all of which function to impair 
hydrolysis of the GTP bound in the active site of RAS, by either preventing RAS 
association with its GAPs (codons 12 or 13 mutations) or by interfering with the 
water molecule required for nucleophilic attack on the γ-phosphate of GTP (codon 
61 mutations) [36]. This causes RAS to remain in the active GTP-bound state 
for extended periods of time, promoting its oncogenic effects [36]. About 30% of 
human cancers have a mutated RAS protein [39,42]. RAS can also be functionally 
activated through deregulation of upstream signal transduction components such 
as activation of EGFR [46], or by loss of a GAP, such as NF1 [47]. As such, there 
exist at least three distinct ways that lead to continued activation of RAS in cancer: 
1) acquisition of an activating mutation, 2) RAS activation through deregulation 
of upstream signaling leading to increased RAS GEF activity, and 3) loss of RAS 
GAP function necessary to terminate activity of RAS [39]. Once RAS is activated, 
an interaction is possible with more than 20 effectors that leads to the regulation 
of numerous cell responses, such as proliferation, survival and differentiation 
[36,45,48,49]. 
Among these effectors, RAS is capable of activating the three closely 
related RAF proteins (RAF1, BRAF and ARAF), leading to the activation of the 
MAPK pathway and G1-S cell cycle progression. This pathway activation also 
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promotes the induction of angiogenesis through ERK-mediated transcriptional 
upregulation of angiogenic factors. Furthermore, ERK promote increased tumor 
invasiveness by elevating expression of matrix metalloproteinases. A second 
effector RAS can interact directly with is PI3K. This results in the activation of AKT 
and PDK1 pathways, promoting cell survival. RAS also activates the RALGDS 
pathway to overcome factors inducing cell cycle arrest and apoptosis. The ability 
of activated RAS to interact with numerous downstream effectors enforces its role 
as a promoter of various characteristics of malignant transformation. Therefore, 
targeting the RAS pathway is crucial for tumors expressing aberrant activation of 
this pathway [38]. 
1.3.2  Targeting the RAS Pathway
Among the RAS genes, KRAS mutations encompass 86% of all RAS 
mutations. Indeed, 21.6% of all human cancers harbor KRAS mutations. The need 
for KRAS inhibitors is especially pronounced in pancreatic, colon and lung cancers 
which frequently harbor K-RAS mutations, the predominantly mutated RAS gene in 
three of the top four mortality-associated neoplasms in the United States [35,36,42]. 
Currently, there are no available drugs that can shut down KRAS directly [42,50]. 
Finding KRAS inhibitors has been previously regarded as the Holy Grail of cancer 
research [51]. Unfortunately, targeting KRAS directly has proven to be vexing and 
quite difficult [35,36,45,48,51]. Historically, the most studied RAS gene has been 
HRAS, which ironically is the least frequently mutated [38,42]. This paved the way 
for RAS inhibitor studies on HRAS, leading to the discovery of farnesyltransferase 
inhibitors (FTIs) which successfully inhibit the transportation of HRAS onto the 
plasma membrane [38]. However, these inhibitors failed to function effectively on 
K-RAS due to the protein’s increased affinity towards farnsesyltransferases and its 
ability to receive a geranylgeranyl isoprenoid, which can substitute for the farnesyl 
13
group and support membrane association of the protein and transforming activity 
[35,38,42-44,52]. After the failure of FTIs in the clinic, researchers have attempted 
to use farnesylthiosalicylic acid (FTS), which functions to dislodge RAS from the 
plasma membrane and making it susceptible to protein degradation [42]. However, 
a clinical trial conducted on NSCLC has shown FTS fails to elicit tumor regression 
[53]. 
Since RAS is required to be bound to GTP for activation, a possible 
approach to inhibit RAS would be to design a small molecule capable of displacing 
the GTP from the RAS protein [39]. This approach was encouraged in the light of 
the success observed with small molecules competing against ATP for the active 
site of protein kinases [54]. Unfortunately, competing for the nucleotide binding 
site in RAS is not a promising approach for targeting activated RAS. This is due to 
the inherent kinetic properties of Ras:GTP binding, which is marked by a very high 
affinity (picomolar range) in the context of millimolar cytosolic GTP levels [39,55]. 
Conversely, the affinity of protein kinases for ATP is usually in the micromolar 
range in the context of millimolar cytosolic ATP. Therefore, the nanomolar 
affinity that can be accomplished with small molecule inhibitors is sufficient for 
successful competition and kinase inhibition [39,56].  However, there has been 
recent progress in targeting RAS protein-protein interactions necessary for RAS 
to acquire a GTP molecule. Indeed, in vitro experiments using peptides such as 
hydrogen bond surrogate (HBS) helices to block the interaction of wild-type RAS 
with one of its GEFs, SOS, have produced promising results [44]. Furthermore, 
a similar approach was adopted with the small molecules have been shown to 
block mutant KRAS interaction with SOS with equally promising results [43,57]. 
Lastly, efforts to target KRAS directly have witnessed a promising advancement 
with the development of small molecules that are capable of irreversibly binding 
and inhibiting a specific form of mutant KRAS. These compounds bind and inhibit 
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KRAS G12C by relying on the cysteine found in the mutant, thereby not affecting 
the wild-type protein. Indeed, this study has identified a new allosteric regulatory 
site on KRAS that is targetable in a mutant-specific manner [58].
The focus of RAS pharmacology inhibition strategy has shifted towards the 
development and utilization of selective inhibitors of the downstream pathways that 
are driven by RAS. Current strategies to shut down the RAS pathway have focused 
on inhibiting downstream effector pathways influenced by RAS, such as MAPK and 
PI3K and RalGEF [42,50]. Indeed, among these downstream pathways, inhibition 
of the MAPK pathway through MEK targeting has recorded promising results in 
cell lines with mutant RAS [59]. However, since the RAS pathway is complex, with 
various signaling branches driven by activated RAS, it is difficult to obtain effective 
overall inhibition by shutting down one effector pathway [39,42]. Consistent with 
this situation, preclinical studies have indicated increased antitumor effectiveness 
when the RAF-MEK-ERK and PI3K-AKT-mTOR arms of the RAS pathway are 
simultaneously targeted in RAS-active tumors. The formation of lung tumors driven 
by mutant KRAS in mice was inhibited only with concurrent treatment inhibition of 
MEK, PI3K and mTOR [60]. Similar results were observed in human melanoma 
cells when synergistic inhibition was recorded with co-targeting Raf-MEK-ERK and 
PI3K-AKT-mTOR pathways using RAF and AKT/mTOR inhibitors concurrently [61]. 
As a result, this project will aim to investigate potential combinations of clinically 
developed and available singular and combinatorial treatment of small molecules 
that can inhibit upstream or downstream components of the RAS pathway. This 
work is described in Chapter 2 of this dissertation. The next sections in the 
introduction will provide the background necessary for proper comprehension of 
the work described in Chapter 3.
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1.4  Basal-like and Claudin-low Breast Cancer
Breast cancer affects more than 1.3 million women worldwide each year, 
making it the second most frequent type of cancer, immediately behind lung cancer. 
It is by far the most diagnosed cancer in women, making up 23-25% of all new 
cancer cases [25,62]. In the United States, an estimated 232,670 new cases of 
invasive breast cancer are expected to emerge among women and approximately 
2,360 cases are expected in men for the year of 2014. An estimated 40,430 
breast cancer deaths (40,000 women, 430 men) are expected to occur, ranking 
breast cancer second (lung cancer being first again) as a cause of cancer death 
in women. Death rates for breast cancer have steadily decreased in women since 
1989, with larger decreases recorded in younger women. This decrease in breast 
cancer mortality rates can be attributed in part to the technological advancement 
in early detection methods, improved clinical treatment strategies, and possibly 
decreased incidence as a result of declining use of menopausal hormone therapy. 
The 5-year relative survival rate for female breast cancer patients has improved 
from 75% in the mid-1970s to 90% today [27]. 
Breast cancer is a heterogeneous disease, constituting multiple types 
associated with distinctive histological and biological features, as well as clinical 
presentations, behaviors and therapeutic response [63-65]. With the advancement 
of surgical procedures leading to breast-conserving therapy, a necessity emerged 
to accurately stratify patients based on relative risk of recurrence or progression. 
This led to the generation of a classification system that incorporated molecular 
histological markers such as the estrogen receptor (ER), progesterone receptor 
(PR), the human epidermal growth factor receptor 2 (HER2) to assess breast 
cancer subtype and risk [66]. Upon diagnosis, patient tumors are classified 
into one of four pathological subgroups based on whether the tumors express 
the estrogen receptor (ER positive) or the progesterone receptor (PR positive), 
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overexpress one of the members of the human epidermal-growth-factor receptor 
family (HER2 positive), or none of these (triple negative breast cancer) [67]. 
Among these, hormone receptor positive breast cancer has a better 5-year 
survival rate likely due to the effectiveness of endocrine therapy on the specific 
cancer, the decreased likelihood of recurrence and the less aggressive nature of 
the disease [68,69]. Meanwhile, targeted therapy for HER2 positive breast cancer 
exists through Herceptin, a monoclonal antibody capable of downregulating the 
activation of HER2, improving survival chances [15]. Triple-negative breast cancer 
(TNBC) on the other hand represents an important clinical challenge due to the 
lack of response to endocrine therapy or other available targeted agents. TNBCs 
exhibit similar metastatic potential to that of other breast cancer subtypes, but are 
associated with a shorter median time to relapse and death  [70]. It is the subtype 
with the worst overall and disease free survival [69].
However, such a limited pathological classification system that incorporates 
only four receptors has been unable to account for the vast molecular heterogeneity 
inherent in breast cancer. For that purpose, global gene-expression analyses 
of breast cancer has been instrumental in providing additional insights into the 
heterogeneous nature of the disease and expanded on the understanding of breast 
cancer formation, progression, recurrence and treatment [65,71-75]. Landmark 
studies by Perou et al. and Sørlie et al. have identified a gene expression-based 
classification system of breast cancer that more accurately encompasses the 
genomic and prognostic diversity of breast tumors [65,74]. Gene-expression 
classification has characterized five molecular subtypes of breast cancer, identified 
as Luminal A, Luminal B, HER2-enriched, Claudin-low and Basal-like, with subtype 
variations in incidence, survival and treatment response [65,74-77]. Among these 
genomic classes, breast cancer patients diagnosed with Claudin-low and Basal-
like breast tumors exhibit predominantly poor prognosis and suffer from limited 
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treatment options [78]. The next section covers the molecular characteristics and 
the clinical attributes of these Basal-like and Claudin-low breast cancers.
1.4.1  Molecular Characteristic of Basal-like and  
Claudin-low Breast Cancer
The Basal-like subtype is characterized by expressesing genes usually 
found transcribed in the normal breast myoepithelium such as high molecular 
weight cytokeratins (CK) such as CK5, 6, 14 and 17, P-cadherin, vimentin, fascin, 
caveolin 1/2, nestin, CD44 and EGFR [71,72]. In fact, it is primarily the expression 
of the cytokeratins that give rise to their description as Basal-like. These particular 
cytokeratins are also found expressed in the basal epithelial cells of the skin and 
airways [72]. Interestingly, Basal-like breast tumors also express luminal epithelium 
genes such as CK8/18 and Kit, but at levels significantly lower than those of found 
in luminal carcinomas [71]. Moreover, Basal-like subtype tumors cells frequently 
carry deficiencies in RB1, BRCA1 and TP53, promoting accelerated cell division 
[71,78]. Indeed, breast tumors carrying germ-line mutations in the BRCA1 are part 
of the Basal-like subgroup. This is the case since alterations that involve a decrease 
in the function of the BRCA1 gene prime development of basal-like tumors, lack of 
expression of ER and poor prognosis [71]. Moreover, a high rate of aneuploidy is 
observed in these tumors, potentially due to the loss of optimal function of these 
three proteins [78]. 
The Basal-like breast cancer subtype constitutes approximately 10-25% of 
all breast carcinomas and generally appears at an early age, predominantly in 
woman of African origin [71]. Pathologically, the tumors tend to be large in size at 
the time of diagnosis and of high histological grade and an elevated risk of lymph 
node infiltration. These tumors lack the expression of the three key receptors in 
breast cancer ER, PR and HER2, making them part of the triple negative breast 
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cancer phenotype. Thus in the clinic, the terms “Basal-like” and “triple negative” 
are often interchanged. However, it is important to note that these terms are not 
equivalent since a discordance of up to 30% between the two groups has been 
recorded [71,78]. This molecular subtype of breast cancer exhibits an aggressive 
pattern of metastatic relapse with predominant targeting of visceral organs, mainly 
lung, central nervous system and lymph nodes. Basal-like tumors generally exhibit 
a worse prognosis than luminals, as well as a high cancer relapse rate in the first 
3 years, in spite of their high response to chemotherapy [71,74]. Therefore, it is 
crucial to identify new therapeutic targets to improve treatment options. 
Interestingly, the Claudin-low group of breast tumors shares some genomic 
similarities with the Basal-like subtype such as the minimal expression of the 
HER2 and the luminal gene clusters [79]. Claudin-low breast tumors occur in 
approximately 12–14% of all breast cancer cases, clinically corresponding to high 
grade infiltrating ductal carcinomas, with metaplastic or medullary differentiation, 
and treatment resistance. Similar to Basal-like tumors, Claudin-low tumors are 
mostly triple negative (about 20% are hormone-positive) and exhibit a poor long-
term prognosis. Furthermore, although BRCA1 mutations are most common 
in Basal-like tumors, they also tend to occur within the Claudin-low subtype. 
However, Claudin-low breast cancers remain a unique subgroup of breast tumors 
on their own, characterized by lacking cell–cell junction proteins, and having a 
concentrated immune cell infiltrate, stem cell properties, and features of epithelial–
mesenchymal transition (EMT). Indeed, Claudin-low tumors have a low expression 
of tight junctions and cell–cell adhesion genes such as claudin 3, 4, 7, occludin, and 
E-cadherin. These tumors also highly express many mesenchymal genes such as 
vimentin, Snail 1 and 2, and Twist 1. This downregulation of epithelial cell traits 
and upregulation of mesenchymal features is reminiscent of the characteristics 
associated with stem cells [71,72,75,76,80]. Indeed, Creighton et al. observed 
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statistically significant enrichment for tumor-initiating cells or cancer stem cells in 
Claudin-low primary mammary tumors [81].   
Due to the nonluminal nature of these two subtypes, and the lack of known 
protein targets on these cancers, limited treatment options are available. As 
such, there exists an urgent need to identify potential targets, biomarkers and 
therapeutics that can improve patient prognosis. One of the promising therapies 
being investigated are inhibitors of PARP1, a key player in the repair of DNA single-
stand breaks [75]. As described earlier, both Basal-like and Claudin-low tumors 
commonly carry BRCA1 mutations [75,82].  Defects in the proper function of BRCA1 
pathway results in deficient homologous recombination repair of the DNA. This 
leads to the accumulation of genetic aberrations that drive carcinogenesis [75]. 
The inhibition of PARP1 in tumors with dysfunctional BRCA1 leads to the accrual 
of collapsed replication forks, DNA double-strand breaks, and cell death [83]. 
Indeed, the addition of iniparib, a PARP1 inhibitor, to combination chemotherapy 
improved the clinical benefit and survival of patients with metastatic triple-negative 
breast cancer (a breast cancer subtype frequently found with BRCA1/2 mutations) 
without significantly increased toxic effects [84]. Furthermore, other DNA-repair 
pathway-related genes such as CHK1 are usually found highly expressed in Basal-
like breast cancers, suggesting that these tumors may be under a continuous state 
of DNA-repair, which may not be the case in Claudin-low tumors [75]. Interestingly, 
however, this dissertation describes the increased sensitivity of both Basal-like 
and Claudin-low breast cancers to targeted CHK1 inhibition in Chapter 3. Another 
critical pathway in both these breast cancer subgroups identified in Chapter 3 
is AMPK (AMP-activated protein kinase). As such, the next section will provide 
a proper background on both of these pathways, and their documented role in 
cancer.
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1.4.2  The AMPK and CHK1 pathways
AMPK is a heterotrimeric serine/threonine kinase complex (comprising 
α, β, and γ subunits) that is a key regulator of cellular metabolism and energy 
homeostasis in mammalian tissues. AMPK is regulated by AMP/ATP ratios in the 
cell and functions as part of an evolutionarily conserved energy-sensing pathway 
[85,86]. Upon the exposure of a cell to nutrient deprivation or hypoxic stress, the 
catalytic α subunit of AMPK is phosphorylated at threonine 172 by upstream kinases 
such as LKB1, CAMKKβ, and TAK1. This leads to an allosteric activation through 
AMP binding to the regulatory γ subunit [87]. The activation of  AMPK signaling 
restores metabolic homeostasis by 1) reducing energy consumption by decreasing 
the synthesis of protein, lipid, and fatty acids; 2) increasing energy production by 
upregulating glucose and fatty acid uptake, glycolysis, fatty acid oxidation; and 3) 
promotion of angiogenic regulators such as VEGF [88]. AMPK is also capable of 
directing cell fate by promoting apoptosis through the direct phosphorylation of p53 
or by promoting cell survival through activating the ULK1-autophagy axis [89,90]. 
The collective effects of AMPK signaling activation lead to the protection of cellular 
integrity by blocking the advancement of the cell cycle progression when insufficient 
resources are available for the cell [88]. The activation of AMPK results in ATP 
conservation via the activation of catabolic metabolism pathways and inhibition 
of anabolic processes that consume ATP. The end result of AMPK activation is 
escape from bioenergetic catastrophe and cell death through the conservation of 
cellular energy [86]. 
Interestingly, the role of AMPK in cancer is dichotomous; AMPK can exert 
pro- or antitumor effects based on cellular context. AMPK is central to a tumor 
suppressor network, the LKB1-AMPK-TSC-mTOR signaling cascade, known to 
regulate cell growth and proliferation in response to stress [91]. Loss of AMPK 
can cooperate with oncogenes such as BRAF and MYC to reprogram tumor cell 
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metabolism and promote rapid cell growth and proliferation [92,93]. Conversely, the 
activation of AMPK can also provide a growth advantage to cancer cells. Activation 
of AMPK in response to hypoxia and nutrient deprivation stresses provides 
cancers cells with the metabolic flexibility necessary for survival. AMPK promotes 
this metabolic plasticity through several mechanisms such as inducing autophagy, 
fatty acid oxidation, and maintenance of intracellular NADPH [86]. These opposing 
roles of AMPK highlight the complexity of the kinase’s role in the cancer cell. 
Pharmacologically, interest in the tumor suppressive role of AMPK has 
gained ground as evidence has emerged to show the antitumor effects of AMPK 
activation. AMPK agonists, such as the biguanides metformin and phenformin used 
to treat type II diabetes, have been investigated as potential cancer therapies. 
Metformin treatment has been observed to be associated with a significantly lower 
cancer incidence in patients relative to those using other medications to manage 
their diabetes [94]. However, recent work has indicated that the antitumoregenic 
effects of metformin and another known AMPK agonist, AICAR, are due to AMPK-
independent effects [95]. Conversely, other studies have implicated AMPK as 
a mediator of cellular proliferation and survival, showing the promising effect of 
AMPK inhibition as a cancer therapy. Indeed, studies have shown that treating 
prostate cancer and glioblastoma cells with dorsomorphin c, an inhibitor of AMPK, 
leads to a reduction in cell growth [96,97].
The second pathway discussed in Chapter 3 as a potential target of Basal-
like/Claudin-low breast cancer is the CHK1 pathway. CHK1 is a serine/threonine 
kinase activated in response to a diverse array of genotoxic insults. CHK1 assumes 
the role of the major cell-cycle checkpoint kinase mediating S- and G2-arrest 
[98]. CHK1 is also important for the stabilization of stalled replication forks, the 
control of replication origin firing and replication fork progression, and homologous 
recombination [99]. The key role of CHK1 is to relay the checkpoint signals from 
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the proximal checkpoint kinases ATM, ATR and ATX. CHK1 is primarily activated 
by ATR-mediated phosphorylation following the formation of double strand or 
single-strand DNA breaks, the latter being its main activator. This leads to the 
phosphorylation of downstream components such as TP53, CDC25 and TLK1/2 
that promote apoptosis, cell cycle arrest and chromatin remodeling [100,101]. 
The rationale behind targeting CHK1 in cancer hinges upon the goal of 
inducing toxic levels of replication stress (RS) that leads to cell death [101]. RS 
is defined as the delaying or stalling of DNA synthesis and/or replication fork 
progression [102]. A certain degree of RS occurs during regular cell division, where 
it is normally detected and dealt with by the ATR and CHK1. Inhibiting these proteins 
leads to an increase in the occurrence of RS, which can ultimately lead to cell 
death by p53-independent means. As such, targeting CHK1 could be particularly 
toxic in cells carrying high endogenous levels of RS. Importantly, although tumors 
in general might normally carry certain degree of RS, inhibiting CHK1 then would 
only be toxic for those tumors harboring distinctly high levels of RS [101]. Therefore, 
it is important to identify the subpopulation of tumors sensitive to CHK1 inhibition. 
Indeed, studies have identified the effectiveness of single-agent CHK1 inhibition 
against neuroblastomas and MYC-driven lymphomas [103-105]. In breast cancer, 
the rationale of CHK1 targeted therapy use is supported by the well-documented 
evidence of alteration in the DNA damage repair machinery through either the high 
rate of BRCA or P53 mutations in the Basal-like/Claudin-low and triple negative 
subtypes [71,72,78]. Therefore, targeting CHK1, a DNA damage repair component 
may lead to the cell’s inability to properly fix chromosomal damage, leading to 
accumulation of RS and cell death. Indeed, Albiges et al. have shown CHK1 
as a potential target in TNBC using genomic analyses. Furthermore, the group 
described the induction of mitotic cell death upon treatment with CHK1 inhibition, 
and the effectiveness of the treatment on two TNBC cell lines [98]. 
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1.5  Dissertation Overview
Overall, the goal of this dissertation is to incorporate personalized medicine 
approaches for treating cancer subtypes driven by complex or uncharacterized 
signaling pathways. To this extent, two different complex cancer phenotypes 
were targeted: RAS-driven NSCLC and Basal-like and Claudin-low breast cancer 
(BL-CL). Genomic analyses were used to characterize these phenotypes on a 
molecular level, and this information incorporated into high-throughput drug 
screening to identify novel therapeutic leads. Once a candidate treatment was 
identified, it was evaluated biochemically for the identification and description of 
the mechanism of action. Chapter 2 is a published manuscript that discusses the 
work performed to identify a personalized treatment strategy against RAS-driven 
NSCLC.  Chapter 3 is a manuscript submitted to the AACR Journal of Molecular 
Cancer Therapeutics that focuses on the identification of a novel sterol sulfate that 
is personalized against BL-CL. This dissertation is concluded by Chapter 4, which 
provides a summary of the major points presented, and a discussion of how the 
work described here has impacted the field of personalized medicine and targeted 
therapy, with a view on future directions and outlook.
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A B S T R A C T
Better approaches are needed to evaluate a single patient’s drug response at the genomic
level. Targeted therapy for signaling pathways in cancer has met limited success in part
due to the exceedingly interwoven nature of the pathways. In particular, the highly com-
plex RAS network has been challenging to target. Effectively targeting the pathway requires
development of techniques that measure global network activity to account for pathway
complexity. For this purpose, we used a gene-expression-based biomarker for RAS network
activity in non-small cell lung cancer (NSCLC) cells, and screened for drugs whose efficacy
was significantly highly correlated to RAS network activity. Results identified EGFR and
MEK co-inhibition as the most effective treatment for RAS-active NSCLC amongst a panel
of over 360 compounds and fractions. RAS activity was identified in both RAS-mutant and
wild-type lines, indicating broad characterization of RAS signaling inclusive of multiple
mechanisms of RAS activity, and not solely based on mutation status. Mechanistic studies
demonstrated that co-inhibition of EGFR and MEK induced apoptosis and blocked both
EGFR-RAS-RAF-MEK-ERK and EGFR-PI3K-AKT-RPS6 nodes simultaneously in RAS-active,
but not RAS-inactive NSCLC. These results provide a comprehensive strategy to person-
alize treatment of NSCLC based on RAS network dysregulation and provide proof-of-
concept of a genomic approach to classify and target complex signaling networks.
ª 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.
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1. Introduction
Cancer is among the principal causes of disease in the world,
with an approximated 12.7million new cancer cases occurring
in 2008 (International Agency for Research on Cancer and
Cancer Research UK, 2012). The RAS proto-oncogenes are
frequently mutated in human cancers, with constitutively
active mutations observed in approximately one third of hu-
man tumors (Baines et al., 2011; Downward, 2003; Riely
et al., 2009). In humans, three genes encode four different
RAS proteins: HRAS, NRAS, KRAS-4A and KRAS-4B, the latter
two being alternative splice variants of the KRAS gene
(Pylayeva-Gupta et al., 2011). These highly homologous
GTPase proteins, sharing 90% amino acid identity (Baines
et al., 2011), localize to the cytosolic part of the plasma mem-
brane, where they cycle through “on” (GTP-bound) and “off”
(GDP-bound) states (Downward, 2003; Karnoub and
Weinberg, 2008). RAS can be switched on through multiple
mechanisms, such as via receptor tyrosine kinases like EGFR
and other growth factor receptors like PDGFR and IGFR
(Bazenet and Kazlauskas, 1993; Chan et al., 2001; Innocenti
et al., 2002; Ono and Kuwano, 2006; Repasky et al., 2004), or
by obtaining activating mutations in the gene (Downward,
2003). The most common RAS mutations occur in codons 12,
13 and 61 (COSMIC Database; Schubbert et al., 2007), all of
which impair hydrolysis of GTP (Downward, 2003). These var-
iants cause RAS to remain in an active GTP-bound state, pro-
moting its oncogenic effects for extended periods of time
(Pylayeva-Gupta et al., 2011). Activated RAS can interact with
more than 20 effectors to regulate various cellular responses,
including cellular proliferation, survival and differentiation
(Cox and Der, 2010; Der, 2012; Pylayeva-Gupta et al., 2011;
Schubbert et al., 2007). Despite extensive efforts, the RAS pro-
teins have remained undruggable targets (Baines et al., 2011)d
no therapies exist in the clinic to directly treat RAS-active tu-
mors (Baines et al., 2011; Gysin et al., 2011).
Targeting the RAS pathway would be beneficial for lung
cancer, the leading neoplasm in incidence and mortality in
the world (International Agency for Research on Cancer and
Cancer Research UK, 2012). KRAS mutations occur in 20e30%
of non-small cell lung cancers (NSCLC), which make up 87%
of all lung cancer cases; thesemutations occur predominantly
in the adenocarcinoma subtype of NSCLC (Aviel-Ronen et al.,
2006; Graziano et al., 1999; Minna and Larsen, 2011; Roberts
et al., 2010), and they represent the most common molecular
change in NSCLC (Roberts and Stinchcombe, 2013). In the
US, an estimated 228,190 new cases of lung cancer are pre-
dicted to have occured in 2013,with an approximate 70% fatal-
ity rate (American Cancer Society, 2013). The 5-year survival
rate for lung cancer has only modestly improved since 1975,
increasing from 12% in 1975 to 16% in 2007. Lung cancer today
still accounts for more deaths than any other cancer in both
men and women, killing almost three times as many men as
prostate cancer, and almost twice as many women as breast
cancer (American Cancer Society, 2013). The survival rate is
even worse for KRAS positive lung cancer patients (Guan
et al., 2013; Johnson et al., 2012; Meng et al., 2013; Roberts
and Stinchcombe, 2013), highlighting the desperate need for
novel therapeutics that can treat RAS-active tumors.
The RAS pathway is a large and complicated signaling
cascade, comprising a network as opposed to a linear
pathway. It is composed of numerous interacting proteins,
upstream and downstream of RAS, providing feedback and
crosstalk to the different components of the pathway (Stites
et al., 2007). Together, these components establish and pro-
mote tumorigenic effects in the cell (Cox and Der, 2010;
Pylayeva-Gupta et al., 2011). Numerous growth factor recep-
tors, such as EGFR, PDGFR and IGFR are among the upstream
proteins that can activate the RAS pathway (Bazenet and
Kazlauskas, 1993; Chan et al., 2001; Innocenti et al., 2002;
Ono and Kuwano, 2006; Repasky et al., 2004); downstream
effector proteins include ERK, PI3K, and RPS6, which each
have been shown to have primary roles in cell proliferation
and survival (Fan et al., 2009; Schubbert et al., 2007). Thus, tu-
mors cells can have an activated RAS pathway by dysregula-
tion of up or downstream pathway components, even
without harboring a RAS mutation. Relying on biochemical
analysis of RAS through mutation testing and measuring
the active form of RAS (GTP-bound form) as means to record
RAS-pathway activation status is limited; the existence of
mutated RAS does not necessarily predicate an oncogenic
addiction to the RAS pathway, as it has been previously
shown that KRAS dependency is widely variable in KRAS-
mutant cancer cell lines. Therefore, cancer cells may harbor
a mutation in RAS, but not necessarily be addicted and
dependent on the continual signaling of the pathway (Singh
et al., 2009). Furthermore, if RAS is not mutated, it cannot
be assumed that the network is “off”, as additional compo-
nents of the network may still be activated. In addition to
redundancy in the network, the relative importance of
different RAS network components may be context depen-
dent; thus, focusing on a single protein might limit the ability
to accurately reflect activity (Downward, 2006). Therefore, it
is critical to study RAS-pathway activation in a comprehen-
sive manner; we use a genomics framework to accomplish
this goal.
In order to effectively measure activity in the RAS network,
we utilize a RAS gene-expression signature capable of
providing a network-scale measurement of activation by
measuring the acute transcriptional changes that occur after
RAS activation (Bild et al., 2006). As RAS can be activated by
many mechanisms, it is critical to measure the RAS network
more comprehensively than just by analysis of mutation sta-
tus in order to obtain a reliable predictor of pathway activa-
tion. The need for comprehensive pathway measurements is
especially true for complex branching pathways such as RAS
(Downward, 2006). To that extent, our RAS gene-expression
signature has been previously validated to accurately predict
RAS-pathway activity in a variety of diverse settings;
including 1) prediction of activity in primary human NSCLC
adenocarcinoma tumors (Bild et al., 2006), 2) predictions of
RAS activity in a multitude of cancer subtypes represented
in Oncomine (Rhodes et al., 2007), 3) measurement of RAS-
pathway activity in gastric cancer and ER þ breast cancer
bone metastasis (Ooi et al., 2009; Zhang et al., 2009) 4) and
analysis of K-RAS dependency signature genes and “RAS
addiction” in primary lung tumors (Singh et al., 2009).
Together, these studies provide support to the robustness
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and accuracy of the RAS signature to analyze RAS network
activation in multiple settings.
In this study, we develop a network-based genomics
framework for drug discovery. Specifically, we use a RAS
gene-expression signature to discover therapeutic regimens
that target the RAS network in lung cancer. We used this
signature to determine RAS activity in a panel of NSCLC cell
lines e these RAS-pathway activity measurements for each
cancer sample are on a continuous scale, and can be corre-
lated with drug response across the panel of cancer cell lines
activity (West et al., 2001). Therefore, we identify compounds
whose efficacy correlates to the genomics-based measure-
ment of RAS activity in a drug screen that included 366 known
and novel drug compounds. The results from the genomics-
based drug screen identified that combined inhibition of
EGFR and MEK pathway components most effectively
inhibited RAS-active tumor cells. Indeed, there was a highly
significant and reproducible correlation between treatment
response and RAS-pathway activity in a large panel of lung
cancer cell lines, highlighting the ability of this drug combina-
tion to selectively block tumor cells with RAS activation inde-
pendent of the manner in which the RAS pathway is turned
on. Additional novel compounds or drug regimens that target
other components of the RAS network were not as effective at
inhibiting RAS-active tumor cells. We show that in combina-
tion, these treatments block both the EGFR-RAS-RAF-ERK
and EGFR-PI3K-AKT-RPS6 nodes of the RAS-pathway network
and induce apoptosis, while either drug alone did not effec-
tively inhibit both nodes. These results indicate that EGFR-
RAS-RAF-ERK and EGFR-PI3K-AKT-RPS6 are key nodes impor-
tant for RAS-activated lung cancer tumor cell survival. Our
study combines genomic profiling with a high-throughput
drug screen to guide the discovery of treatments that can be
used to target certain cancer phenotypes. This approach can
individualize drug therapies to target signaling pathways
more efficiently through gene-expression profiling of network
activation (Ascierto et al., 2013; Bentley et al., 2013; Favata
et al., 1998; Janne et al., 2013; To et al., 2012).
2. Materials and methods
2.1. Small molecules
Gefitinib, AEW541, erlotinib, trametinib, U0126, sorafenib, and
temsirolimus were purchased from Selleckchem and dissolved
in 100% DMSO to generate 100 mM stock solutions of each,
stored at �80 �C. For erlotinib, the 100 mM stock solution was
further diluted to 30 mM in 100% DMSO for complete solubil-
ity. Novel compounds were provided by Dr. Chris Ireland
and Dr. Sunil Sharma at the University of Utah.
2.2. Genomic data acquisition and normalization
Weused gene-expressionmicroarray data that had previously
been used to profile the transcriptomic effects of RAS-
pathway activation (Barbie et al., 2009; Bild et al., 2006;
Boutros et al., 2009; Chang et al., 2009; Kim et al., 2009;
Watanabe et al., 2011). We downloaded gene-expression
microarray data for lung cancer cell lines from the Cancer
Cell Line Encyclopedia (CCLE) (Barretina et al., 2012). Collabo-
rators at Duke University also provided gene-expression
data for 56 lung cancer cell lines. This dataset was uploaded
to the Gene-Expression Omnibus (GEO) under accession iden-
tifier GSE47206. We MAS5 normalized (Hubbell et al., 2002)
these datasets using the affy Bioconductor package (Gautier
et al., 2004) for our analysis.
2.3. RAS-pathway activation predictions
Using the RAS gene-expression signature (Barbie et al., 2009;
Bild et al., 2006; Boutros et al., 2009; Chang et al., 2009; Kim
et al., 2009; Watanabe et al., 2011), we predicted RAS-pathway
activation for each cell line using the Bayesian binary regres-
sion algorithm version 2.0 (BinReg2.0) used as a MATLAB
plug-in (West et al., 2001). Prior to making the predictions,
the data were log2 transformed and DWD normalized
(Benito et al., 2004) to reduce biases that can result from differ-
ences in batch processing and microarray platforms. In mak-
ing the predictions, we used default parameters, except that
our signature used 350 genes and 1 metagene (as determined
previously to be optimal for the RAS pathway) (Bild et al.,
2006). The CCLE dataset was used for the expanded lung and
breast cancer cell line predictions, while GSE47206 was used
for the 14 lung cancer pilot experiments. For the pilot screen,
the SK-MES-1 RAS-pathway activation value was obtained
from the CCLE dataset run, as that cell line was not available
in the GSE47206 dataset.
2.4. Preliminary genomics-based drug screen assay
Drugs were serially diluted 1:3 in 8 doses of each drug, starting
from 30 mM and ending with 13.7 nM. To make the highest
doses soluble in aqueous 5% FBS RPMI media solution, the
drugs were sonicated twice on ice, and then used for serial
dilution. For combinatorial treatments, doses had equalmolar
concentrations for each compound. All treatment doses were
performed in four replicates. Cell viability and growth was
measured using CellTiter-Glo (Promega, Madison, Wisconsin)
72 h post-treatment. EC50 values were calculated from dose
response data by plotting on GraphPad Prism 4 and using
the equation Y¼ 1/(1þ 10^((logEC50�X )*HillSlope)) with a var-
iable slope (Ymin ¼ 0 and Ymax ¼ 1). Plots were forced to start
from the x-axis by plotting for an x-intercept point. Predictions
were then correlated against EC50 values of the treatments,
and an unbiased approach was used to identify candidate
therapies by selecting drugs based on Pearson correlation
values of less than or equal to �0.5, significant two-tailed un-
paired t-test p-values ( p < 0.05) and a 95% confidence interval
calculated in GraphPad Prism 6.01.
2.5. Novel compounds and fractions drug screen and
expanded dose response assays
Cell lines were plated at 1500 cells/well. Detailed information
on the cell lines used and their growth conditions is provided
in the Supplementary Information sheet. Cell lines were ob-
tained from ATCC. For the dose response assays, known tar-
geted therapeutics were serially diluted 1:3 from 90 mM to
the lowest dose of 41.15 nM in media containing 5% FBS
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(Gibco/Life technologies, Carlsbad, CA) and 1� AntieAnti
(Gibco/Life technologies, Carlsbad, CA). To make the highest
dose soluble in aqueous media, drugs were sonicated twice
on ice. For combination treatments, doses had equal molar
concentrations for each compound. Cell viability was
measured as described before. Every dose was done at least
in duplicate. Dose response curves were generated using the
same methodology described above. For novel fractions and
compounds used in the screen, two or three doses of each
were used respectively. For the novel compounds, the dose
most negatively correlated to predicted probability of RAS-
pathway activation was represented on the histogram. For
the known targeted therapeutics, drug EC50 correlation to
RAS-pathway activation was plotted.
2.6. Statistical and multivariate analysis
Linear correlation graphs and box plots were created using
Graphpad Prism 6.01, and their corresponding statistical sig-
nificance tests performed using the software. For correlation
plots, a built-in two-tailed significance test calculated by
Graphpad Prism 6.01 was used. Graphpad computes a t ratio
from the Pearson r and the sample size using the Student’s
t-distribution method, and computes p from t values using a
standard algorithm. For box plots, a standard two-tailed Man-
neWhitney U-test was used when two samples were being
compared, with the exception of the box plot diagrams for
erlotinib þ trametinib, where an unpaired t-test with Welch’s
correction was used due to the normality of the data and the
unequal standard deviations. When testing for significance
acrossmore than 2 samples, we adjusted formultiple compar-
isons using GraphPad’s built-in Dunn’s multiple comparisons
test, which compares the mean rank difference among sam-
ples against an a ¼ 0.05. For the Annexin V Apoptosis assay,
Dunn’s multiple comparison significance test was used to
compare the Annexin V positive cell means of the different
drug treatments against the DMSO control, for RAS-active
and RAS-inactive cell lines separately. We sought to model
the multivariate relationship between gefitinib þ U0126 EC50
and the predictor variables: RAS-pathway activity prediction,
tumor subtype (adenocarcinoma, large cell carcinoma, or
squamous cell carcinoma), KRAS mutation, TP53 mutation,
MEK1 mutation, and EGFR mutation. The mutations were
coded as (Y/N) based on observations from the CCLE hybrid
capture sequencing dataset; we used mutations listed as
non-neutral variant SNPs. We then used a two-step approach
to construct a parsimoniousmodel. First, a univariate analysis
was used to determine the set of predictor variables that were
individually associated with gefitinib þ U0126 log10 EC50. t-
tests were used for binary predictors (mutations), and linear
models were used for the continuous predictor (RAS-pathway
activation) and for the ternary predictor (tumor subtype). Only
those variables that were individually significant ( p < 0.05,
unadjusted) were included in the multivariate analysis. The
multivariate analysis was a linear model. The log10 EC50
values were used in the analysis as they were much less
skewed than the mM EC50 values and more closely agreed
with the normality assumptions. The multivariate analysis
was performed using the “R” statistical computing software,
version 2.15.0 (R Development Core Team, 2011).
2.7. Immunostaining and KRAS-GTP pull down
9 NSCLC cell lines with a range of RAS-pathway activation
profiles were used for the protein analysis (H1373, LCLC-
97TMI, SK-MES-1, H441, H1944, H1563, H661, H520, H522).
Cells were treated with 5 mM of gefitinib, U0126,
gefitinib þ U0126 and DMSO control in 5% FBS media and 1�
AntieAnti for 6 h. Cells were washed, lysates extracted and
western blots run (Supplementary Methods). Primary anti-
bodies for GAPDH (#5174S), EGFR (#4267S), pEGFR-Y1068
(#2234S), pRAF1-S289/296/301 (#9431S), pRAF1-S338 (#9427S),
MEK1/2 (#8727S), pMEK1/2-S217/221 (#9154S), pERK1/2-T202/
Y204 (#4370S), pAKT-S473 (#4060S), RPS6 (#2217S), pRPS6-
S240/244 (#5364S) and pRPS6-S235/236 (#4858S) were obtained
from Cell Signaling Technology (Beverly, MA). RAF1 (sc-
373722), AKT1/2/3 (sc-8312), ERK1/2 (sc-292838) and KRAS
(sc-30) antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). The KRAS Activation Assay (Cellbio-
labs, San Diego, CA) was used to pull down RAS GTP,
according to manufacturer’s protocol and run on a western
blot. KRAS-GTP was then blotted for using the described
KRAS antibody.
2.8. Annexin V apoptosis assay
RAS-active cell lines H358, Calu-3, H2122 and RAS-inactive cell
lines H520, H522 and H661 were plated overnight with 400,000
cells per plate in 60mmplates and grown in their correspond-
ing media (Supplementary Methods). The selected cell lines
exhibited high or low probability of RAS-pathway activation,
and the highest or lowest response to the combined therapy
regimen. All cell lines selected were lines that were part of
the drug screens. Cell lines were treated with 1 mM of gefitinib,
U0126, gefitinib þ U0126 or DMSO control, which was prepared
in 5% FBS media and 1� Antieanti, for 72 h, then washed
and collected for Annexin V staining. For the stain, the Dead
Cell Apoptosis Kit with Annexin V Alexa Fluor 488 & Propi-
dium Iodide for flow cytometry (Life Technologies, Carlsbad,
CA) was utilized according to manufacturer’s protocol. Using
flow cytometry analysis, the percentage of Annexin V positive
cells was recorded, and the means of the positive Annexin V
cells (early-stage apoptosis) calculated for the different treat-
ments, separately for the 3 RAS-active cell lines and the 3
RAS-inactive cell lines.
2.9. Erlotinib and trametinib combination dose
response assay
The highest drug combination dose was serially diluted 1:3 in
8 doses, starting from 90 mM and ending with 41.15 nM. To
make the highest dose soluble in aqueous 5% FBS RPMI media
solution, it was sonicated twice on ice, and then used for serial
dilution. Doses had equal molar concentrations for each com-
pound. All treatment doses were performed in four replicates.
Cell viability was measured and EC50 obtained as described
before in the methods. Predictions were then correlated
against EC50 values of the combination treatment using Pear-
son correlation and the built-in GraphPad p-value test for cor-
relation significance and a 95% confidence interval.
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3. Results
3.1. Genomics-based drug screen identifies an effective
regimen for RAS-pathway inhibition
The goal of this research is to develop a pathway-based geno-
mics framework that can be used to discover drugs to effec-
tively inhibit difficult-to-target oncogenic pathways such as
RAS. Complex signaling pathways underlie many diseases,
and it remains difficult to align individual patients with ther-
apies that target these pathways effectively. To address this
need, we developed a genomic approach to identify inhibitors
that target specific pathways (Figure 1). Briefly, we used our
validated genomic signature to estimate the RAS-pathway’s
activity in NSCLC cells (Bild et al., 2006). This activity is repre-
sented by a continuous scale of probability from low to high
(0e1 respectively), and produces a quantitative estimate of
the pathway’s activity in cells. We correlated these genomic-
based pathway activity measurements with cell line response
to in vitro treatment of a large catalog of compounds. We then
identified the compounds whose efficacy correlated best with
genomics-based pathway activity.
The advantages of our drug screening approach are the
following: 1) knowledge of the direct drug target is not neces-
sary and instead focuses on the drug’s effect on overall
pathway activity rather than on any single pathway compo-
nent’s activity; 2) measurement of network activity is more
comprehensive than just mutation status, thereby capturing
all pathway-active cells, and 3) it is relatively high-
throughput in the sense that an unlimited number of genomic
pathway profiles can be applied to all compounds tested in the
drug screen, facilitating the characterization of drug
mechanism.
We carried out an initial drug screen on a panel of 14
NSCLC cell lines, and validated our findings in a two larger
drug screens that included over 35 NSCLC cell lines each. For
our initial screen, we tested several well-characterized small
molecule inhibitors that target different components of the
growth factor receptor network; these inhibitors include the
EGFR inhibitor gefitinib (Mok et al., 2009; Ono and Kuwano,
2006), IGFR inhibitor AEW541 (Garcia-Echeverria et al., 2004),
MEK1/2 inhibitorU0126 (Favata et al., 1998) and amTOR inhib-
itor temsirolimus (Hudes et al., 2007), which were administered
alone and in paired combinations. The drug response data
were then correlated to predicted probabilities of RAS-
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Figure 1 e The overall design of the Screenome approach to find RAS-driven tumor treatments. The RAS gene-expression signature is used to
predict the probability of pathway activation in a panel of cancer cell lines. These same cell lines undergo dose response assays. The EC50 values
are calculated and correlated against the predicted probability of RAS-pathway activation. The treatments whose effectiveness correlated
negatively to RAS activity (the higher the probability of RAS being on, the more sensitive to the drug) are picked out as potential treatments for
tumors with an activated RAS pathway.
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pathway activation in our panel of NSCLC cell lines, obtained
through the use of our RAS gene-expression signature (Bild
et al., 2006) (Figure 1). Our preliminary screen showed a signif-
icant correlation between predicted RAS-pathway activation
and co-inhibition of EGFR and MEK1/2 through the use of gefi-
tinib and U0126, respectively (R ¼ �0.69, p-value ¼ 0.0066)
(Supplementary Figure 1A). A significant correlation between
RAS activity, as defined by the genomic signature, and drug ef-
ficacy did not exist for either of these inhibitors alone
( gefitinib: p ¼ 0.0866, U0126: p ¼ 0.2676), suggesting that the
drugs must be combined to effectively block RAS activity in
NSCLC cells (Supplementary Figure 1B and C). We also inves-
tigated the effects of directly targeting the mTOR component
of the growth factor receptor and RAS pathway, but mTOR in-
hibition through temsirolimus did not lead to growth inhibition
of RAS-active cells, even with coupled inhibition of EGFR and
MEK inhibition (Supplementary Figure 2AeC), and was there-
fore not pursued further.
3.2. Validation of the genomics-based drug screen
results
Next, to validate and further interrogate the relationship be-
tween RAS-pathway activity and response to single and com-
bined drug treatments, we performed multiple larger
genomics-based screens on an expanded panel of 39 NSCLC
cell lines (Figure 2A and Supplementary Figure 3A). In addition
to a panel of well-characterized inhibitors, this larger screen
also included over 360 novel drug-like compounds. As with
the initial genomics-based screen, these experiments vali-
dated that the efficacy of EGFR and MEK1/2 co-inhibition
through gefitinib and U0126 was most correlated to RAS activ-
ity than any other single or combination drug treatments,
resulting in a Pearson R score of �0.57 and p ¼ 0.0002
(Figure 2A and C). Specifically, NSCLC cells with high
genomics-predicted RAS activity (predicted probability of
RAS-pathway activation > 0.5) had significantly lower EC50
scores (drug dose leading to 50% cell survival relative to un-
treated cells) than cancer cells with low RAS activity (pre-
dicted probability of RAS-pathway activation < 0.5),
indicating higher drug sensitivity ( p < 0.0001, Figure 2B). Cell
lines with high RAS averaged an EC50 ¼ 0.436
(log10) ¼ 2.7 mM, while low RAS cell lines averaged an
EC50¼ 1.07 (log10)¼ 11.76 mM. As shown in Figure 2C, no other
single drug/drug combination showed stronger correlation to
RAS-pathway activity. This finding includes other drugs that
target the growth factor receptor pathway such as single agent
EGFR or MEK inhibitors, as well as single agent or combination
therapies such as the RAF inhibitor sorafenib, and novel drug-
like compounds (Figure 2C) (Liu et al., 2006). We compared this
result against findings from a recently published study that
demonstrated efficacy for IGFR and MEK co-inhibition in
RAS-mutant cancers (Molina-Arcas et al., 2013). In our data,
cell responses for MEK and EGFR co-inhibition correlated
more strongly (R ¼ �0.57) to RAS-pathway activity than MEK
and IGFR co-inhibition (R ¼ �0.35).
We also investigated the efficacy of the EGFR or MEK inhib-
itors in isolation. EGFR and MEK inhibition alone had average
EC50 values of 11.87 mM and 10.02 mM respectively in the top
50% of responsive cell lines (Supplementary Figure 3B). In
comparison, the combined treatment with MEK and EGFR in-
hibitors had an average EC50 of 1.83 mM (Supplementary
Figure 3B). Additionally, as shown in Figure 2C and
Supplementary Figure 3C and D, EGFR but not MEK1/2 inhibi-
tion showed an individual correlation to RAS-pathway activ-
ity, albeit not as strongly as the combined therapy (EGFR
inhibition: R ¼ �0.47, p ¼ 0.0027. MEK inhibition: R ¼ �0.26,
p ¼ 0.1068). This result is consistent with observations that
KRAS dependent NSCLC cells exhibit some sensitivity to
EGFR inhibitors (Singh et al., 2009), yet the combination ther-
apy required one-tenth as much drug as gefitinib monother-
apy. Furthermore, the BRAF/CRAF inhibitor sorafenib did not
show a significant correlation to RAS activity, both alone
( p ¼ 0.1247) or in combination with EGFR ( p ¼ 0.455) and
MEK1/2 ( p ¼ 0.5356) inhibitors (Supplementary Figure 4AeC).
In support of this finding, sorafenib also failed to show efficacy
in patients with KRAS mutated NSCLC in the phase III
MISSION trial (Goodman, 2012).
The effectiveness of the EGFR/MEK inhibition as a treat-
ment for NSCLC in general is further highlighted by the overall
synergy of these agents in NSCLC cancer cell lines
(Supplementary Figures 5A and 6A) and the significantly lower
total EC50 scores for combination therapies in comparison
with monotherapies observed across all the NSCLC cell lines
(Supplementary Figure 5B and C). The EGFR þ MEK combina-
tion exhibited a synergistic response relationship for 29 out
of 39 cell lines (74%), signified by a synergy score greater
than one (Figure 6A). Synergy was not as prevalent for
RAF þ EGFR and RAF þ MEK inhibitor combinations
(Supplementary Figure 6BeD).
Finally, the correlation between EGFR and MEK1/2 inhibi-
tors combined efficacy and RAS-pathway activation was
unskewed by the 8 most correlative cell lines
(Supplementary Figure 7A) and potentially NSCLC specific, as
the relationship between RAS-pathway activity and drug
response was not observed in a panel of 35 breast cancer cell
lines (Supplementary Figure 7B), possibly due to the depen-
dency of breast cancer on alternate pathways such as PI3K,
HER2 and the estrogen receptor pathway (Burstein, 2005;
Campbell et al., 2004; Rosen et al., 2010; Sommer and Fuqua,
2001).
3.3. Genomics-based RAS activity predictions, and not
RAS mutation status, significantly correlates to
EGFR þ MEK1/2 inhibitor therapy response
RAS can be aberrantly activated by different mechanisms,
including via activating mutations or through dysregulation
of other growth factor receptor pathway components
(Downward, 2003; Karnoub and Weinberg, 2008; Pylayeva-
Gupta et al., 2011). We investigated the relative treatment
responsiveness for KRAS mutated cells compared to cells
without KRAS mutations. Our studies show that KRAS muta-
tions alone did not account for the responsiveness to com-
bined EGFR/MEK inhibition ( p ¼ 0.577, Figure 3A); however,
when RAS activity was consideredmore broadly bymeasuring
pathway activity via our genomic profiling approach, there
was a significant correlation between EGFR/MEK drug sensi-
tivity and RAS activity ( p ¼ 0.0004, Figure 3B). No significant
relationship existed between RAS mutation and drug
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response for any other inhibitor we tested (Supplementary
Figures 8 and 9). These results highlight the importance of
comprehensively characterizing pathway activity via gene-
expression profiles to link pathway activation with drug
response.
Next, we performed a single and multivariate analysis to
investigate whether the relationship between RAS-pathway
activity and EGFR andMEK co-inhibitionmight be confounded
by factors unrelated to RAS-pathway activity or by mutations
in EGFR and MEK, the protein targets of gefitinib and U0126
respectively. Potential variables that we evaluatedwere tumor
subtype (adenocarcinoma, large cell carcinoma, or squamous
cell carcinoma), KRAS mutation, TP53 mutation, MEK1 muta-
tion, and EGFR mutation, using the adenocarcinoma subtype
as the reference sample (Supplementary Table 1). This was
especially important since as expected, predicted probability
of RAS-pathway activation was the highest in the adenocarci-
noma subtype, in comparison to squamous and large cell car-
cinoma subtypes (Bild et al., 2006) (Supplementary Figure 10).
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Temsirolimus+U0126
Temsirolimus
Figure 2 e Combinatorial inhibition of EGFR D MEK is correlated to RAS-pathway activity in NSCLC. (A) Linear correlation of
GefitinibD U0126 EC50 values with the predicted probability of RAS-pathway activation across 39 NSCLC cell lines. Every dot represents a cell
line, with a y value representing the cell line’s GefitinibD U0126 EC50, and an x value representing the cell line’s predicted probability of RAS-
pathway activation. Response to GefitinibD U0126 is significantly negatively correlated to RAS. Legend[ Red: K-RAS-mutant cell lines, Black:
K-RAS wild-type cell lines. (B) Cell lines of the 39 NSCLC panel were divided accordingly and box plot diagrams of Gefitinib D U0126 EC50
values were plotted. Box boundaries denote the 25e75th percentiles, while the error bars indicate maximum and minimum values. The line inside
the box indicates the median value. Response to GefitinibD U0126 as measured by EC50 values is shown. Cell lines with elevated probability of
RAS activation (predicted probability of RAS-pathway activation> 0.5) were significantly more sensitive to Gefitinib D U0126 treatment than
cell lines with low probability of RAS activation (predicted probability of RAS-pathway activation< 0.5). (C) Frequency Distribution of the
Correlation of Compounds, Drugs and Fractions with the probability of RAS-pathway activation. A panel of 366 novel small molecules was tested
against 39 NSCLC cell lines, and their effects on cell viability correlated to the predicted probability of RAS-pathway activation. These correlation
values were plotted on a histogram. Correlation values of temsirolimus, temsirolimusD U0126 and temsirolimusD gefitinib were obtained from the
14 NSCLC cell line preliminary screen and plotted onto the histogram. GefitinibD U0126 was the treatment most negatively correlated to RAS-
pathway activation.
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subtype and our RAS-pathway activation predictions as the
primary potential predictors of EGFR and MEK1/2 co-
inhibition response (Table 1). NSCLC subtype was considered
as a single variable with two levels (large cell carcinoma and
squamous cell carcinoma), and since one level was significant
at p ¼ 0.05, all levels were included in the multivariate
analysis.
Based on the multivariate analysis (Table 2), response to
EGFR/MEK inhibition was significantly higher in the NSCLC
cell lines with high genomics-based RAS-pathway activity, af-
ter adjusting for subtype ( p ¼ 0.00139). This analysis provides
further support to the validity and potential use of our RAS-
pathway predictions as a biomarker of response to
EGFR þ MEK inhibition in NSCLC. Moreover, these results
show that the ability of RAS-pathway activity to predict
response to combination therapy is not confounded by EGFR
nor MEK1 mutations.
3.4. Combined inhibition of EGFR and MEK1/2 blocks
key downstream components of the RAS pathway and
induces apoptosis in RAS-active, but not RAS-inactive
NSCLC cells
Since a variability of response to EGFR andMEKdual inhibition
was observed between tumor cells exhibiting an active and
inactive RAS pathway, we investigated the potential differ-
ences in signaling effects of this drug regimen in NSCLC


























































































p = 0.0004p = 0.0386
BGefitinib + U0126 Gefitinib + U0126
Figure 3 e Ras gene-expression signature predicts response to combined EGFR D MEK inhibition efficacy which inhibits ERK and RPS6
simultaneously. The cell lines of the 39 NSCLC panel were divided accordingly and box plot diagrams of GefitinibD U0126 EC50 values plotted.
(A) Response to GefitinibD U0126 with respect to the mutation status of KRAS, as measured by EC50 values. KRAS mutation does not predict
response to gefitinib D U0126. (B) Response to Gefitinib D U0126 with respect to mutation status of KRAS and predicted probability of RAS-
pathway activation, were RAS-active cell lines signified cell lines with a predicted probability of RAS-pathway activation> 0.5, and RAS-inactive
cell lines< 0.5. Gene-expression signature prediction of probability of RAS-pathway activation predicts response to Gefitinib D U0126. (C) A
panel of 9 NSCLC cell lines, ranging from high to low predicted probability of RAS-pathway activation was treated with Gefitinib, U0126 and
GefitinibD U0126 at a 5 mM dose for 6 h, and compared to DMSO control in a western blot. Combinatorial treatment inhibits the ERK and RPS6
nodes of the EGFR pathway in cell lines with high probability of RAS-pathway activation.
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effects of EGFR and/or MEK inhibition on components of the
EGFR and RAS pathways in a representative panel of 9 NSCLC
cell lines, ranging from high to low predicted probability of
RAS-pathway activation. In general, combined inhibition of
EGFR þ MEK led to concurrent inhibition of ERK and RPS6
phosphorylation, with variable effects on AKT activation in
cells with higher levels of predicted RAS-pathway activation
(Figure 3C). These cell lines also exhibited a general trend to-
wards RAF1 protein loss, while a decrease in RPS6 protein
was observed regardless of RAS-pathway activation status
(Figure 3C). Conversely, cells with the lowest predicted proba-
bility of RAS-pathway activation (H520, H522) maintained
RAF1 protein expression and activated ERK, AKT and RPS6
regardless of the treatment, with cell line H522 even upregu-
lating the activation of AKT and RPS6, even with significant
RPS6 protein loss (Figure 3C).
While combined inhibition of EGFR and MEK blocked both
ERK and RPS6 activation in cells with higher RAS activation
probability, EGFR monotherapy on the other hand only
inhibited the activation of AKT and RPS6 with little effect on
ERK, while MEK monotherapy only inhibited activation of
ERK with a small effect on RPS6. Furthermore, EGFR mono-
therapy did not inhibit ERK, RPS6 or AKT in cells with the
lowest probability of RAS-pathway activation, while MEK
monotherapy had minimal effects on ERK activation, and
even leading to the activation of AKT in cell line H522, high-
lighting the dual-node effect of the combination therapy.
Interestingly, we observe that the activation pattern of
RPS6 did not correlate to probability of RAS-pathway activa-
tion. In cell lines H1373, 97TMI, H441 and H661, activation of
RPS6 correlated to the phosphorylation of ERK, while in cell
lines SK-MES-1, H1944, H1563, H520 and H522 it correlated to
phosphorylation of AKT (Figure 3C). This is potentially due
to the fact that RPS6 can be phosphorylated by the ERK and
AKT arms of the pathway (Roux et al., 2007). Moreover, MEK
inhibition decreased the ERK-mediated phosphorylation-
dependent feedback inhibition of RAF1 (Ser289/296/301 phos-
phorylation) as expected (Fritsche-Guenther et al., 2011)
(Supplementary Figure 11A). This pattern was more promi-
nent when MEK inhibition was coupled with EGFR inhibition.
Furthermore, a mild decrease in the Ser240/244 phosphoryla-
tion mark of RPS6 was observed, as well as a substantial
decrease in the activating phosphorylation mark of RAF1
(Ser338) (Supplementary Figure 11A). Lastly, we did not
observe the downregulation of ERK activation through MEK
inhibition leading to an activation of EGFR upon MEK inhibi-
tion (Supplementary Figure 11A), as has been observed in co-
lon cancer, marking a difference between the response of
NSCLC and colon cancer to ERK inhibition (Klinger et al.,
2013; Prahallad et al., 2012).
Among the two monotherapies and the dual therapy
tested, gefitinibwas the only treatment to produce RAS inhibi-
tion (Supplementary Figure 11B). One explanation for the fail-
ure of the combined therapy to inhibit RAS is that the
combination of EGFR þ MEK inhibition abrogates the effects
of RAS inhibition by shutting down EGFR due to the removal
of the ERK-mediated negative feedback loop on SOS caused
by the complete inhibition of ERK (Shin et al., 2009)
(Figure 5). In conclusion, dual inhibition of EGFR þ MEK with
gefitinib and U0126, respectively, is capable of shutting down
both RPS6 and ERK in RAS-active tumors, while single agent
treatment only suppresses a single component of the
pathway. This is not the case for RAS-inactive tumors, where
neither monotherapy nor dual therapy using an EGFR and a
MEK inhibitor was able to inhibit activation of ERK, AKT and
RPS6.
Next, we studied the ability of combinatorial therapy to
induce apoptosis in RAS-active or RAS-inactive NSCLC tumor
cells. Interestingly, we observed that upon treating 3 RAS-
active and 3 RAS-inactive cell lines with a dose of 1 mM,
apoptosis is only induced at significant levels in RAS-active tu-
mor cells via combined inhibition of EGFR and MEK
(Figure 4AeC). None of our treatments were capable of
inducing apoptosis in RAS-inactive tumor cells (Figure 4B
and D). These results were in line with the above observations
whereby RAS-inactive cell lines recorded a marked resistance
to EGFRþMEK inhibition, and retained activation of ERK, RPS6
and AKT (Figure 3C). These data highlight the importance of
identifying the most beneficial cancer phenotypes prior to
therapy administration.
In summary, combined inhibition of EGFR and MEK blocks
growth of RAS-active NSCLC tumor cells by concurrent inhibi-
tion of ERK and RPS6. Combinatorial therapy performed
significantly better at targeting RAS-active cells and blocking
ERK and RPS6 than single agent therapy, or with therapies
that target other nodes of the RAS-pathway network
(Figure 5). These observations did not hold true for only RAS-
or EGFR-mutant NSCLC tumor cells, providing evidence to
the importance of utilizing characterization of pathway activ-
ity that allows for multiple mechanisms of pathway
activation.
3.5. Determining RAS-pathway activity is crucial to
identify tumors that are most responsive to EGFR þ MEK
dual inhibition
As gefitinib and U0126 are not FDA-approved small molecule
inhibitors of EGFR and MEK1/2 respectively, we sought to
Table 1 e Univariate predictors of GefitinibD U0126 response
(log10 EC50). Univariate analysis was first used to determine the set
of predictor variables that were individually significantly related to
GefitinibD U0126 response (log10 EC50). t-tests were used for the
binary predictors (the mutations) and linear models were used for the
continuous predictor (RAS-Pathway activation) and the ternary
predictor (Tumor Subtype). The statistical tests used and the p-
values are described. The large cell carcinoma subtype variable level
and the RAS-pathway activity prediction variable were significant
univariate predictors of response.
Predictor Statistical test p-value
KRAS mutation Two sample t-test 0.56
TP53 mutation Two sample t-test 0.55
MEK1 mutation Two sample t-test 0.36
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validate the observation of a correlation between RAS-
pathway activation and response to EGFR þ MEK dual inhibi-
tion by using clinically-relevant inhibitors of EGFR and
MEK1/2. We tested a combination of erlotinib and trametinib,
two FDA-approved inhibitors of EGFR andMEK1/2 respectively
(United States Food and Drug Administration, 2013a,b) on a
panel of 16 NSCLC cell lines with a varying range of RAS-
pathway activation. In support of our previous findings, we
recorded a similar strong and significant correlation between
RAS-pathway activation and response to the combination
therapy (Figure 6A). Moreover, we observe that NSCLC cells
with high genomics-predicted RAS activity had significantly
lower EC50 scores than NSCLC cells with low RAS activity,
indicating higher drug sensitivity ( p ¼ 0.025, Figure 6B). Cell
lines with predicted high RAS averaged an EC50 ¼ �0.6934
(log10) ¼ 0.20 mM, while low RAS cell lines averaged an
EC50 ¼ 0.9545 (log10) ¼ 9.01 mM, a 45-fold difference in sensi-
tivity. As previously observed, there was no difference in
response when the cell lines were divided based on KRASmu-
tation status ( p ¼ 0.553, Figure 6C). These results support the
clinical relevancy of our previous observations with gefitinib
and U0126, and highlight the immediate clinical relevance of
this combinatorial regimen to treat RAS-active tumors in the
clinic.
In summary, we show that determining RAS-pathway acti-
vation status is pivotal to tailor EGFR þ MEK dual inhibition
therapy to the most responsive NSCLC tumors. In Figures 2A
and 6A a strong and highly significant correlation between
RAS-pathway activity and response to EGFR þ MEK combina-
tion therapy is evident. Cell lines with higher probability of
RAS-pathway activation responded significantly better to the
combination therapy (Figures 2B and 6B). The predictive po-
wer of RAS-pathway activity is not confounded by other tested
variables, providing further support to the importance of RAS-
pathway activation status as a determiner of response to
EGFR þ MEK inhibition (Tables 1 and 2). This is important to
note as KRAS mutation status fails to predict response to
EGFR þ MEK inhibition (Figures 3A, B and 6C). The strength
of this correlation lies in its reproducibility, which is observed
in either a small or large sample size, using gefitinib and U0126
(Supplementary Figures 1A, 2A and B) or FDA-approved and
clinically used EGFR and MEK inhibitors in the form of erlotinib
and trametinib (Figure 6). The identification of RAS-active
tumor cells as being most vulnerable to a specific type of
combinatorial therapydin this case EGFR þ MEK inhibi-
tiondemphasizes a need to reassess the design of clinical
studies, with a focus on identifying the potential patient pop-
ulations that could benefit the most from treatments prior to
clinical trial design.
4. Discussion
RAS is a critical target for many solid tumors such as NSCLC;
however, targeting the RAS protein directly has proven
elusive. Furthermore, RAS can be activated by many mecha-
nisms, making it challenging to identify RAS-active tumors.
To discover therapeutics that can target RAS-active tumors,
we performed a genomics-based drug screen in which cancer
cells are characterized for RAS-pathway activity using a gene-
expression signature and then screened against a panel of
compounds to identify those drugs whose efficacy correlates
to pathway activity. By measuring RAS-pathway activity by a
genomics-based biomarker, we are able to more broadly
define RAS activity and are not limited to examiningmutation
status alone. Furthermore, as the pathway predictions
generate a continuous scale of RAS activity, we can identify
drugs and/or drug combinations whose efficacy correlates to
RAS-pathway activity. The genomics-based drug screen has
various advantages compared to alternative drug screens
such as conventional or siRNA screens as it provides a
comprehensive characterization of a pathway’s activity in
cells that is not dependent on biochemical testing, and does
not require knowledge of the direct drug target.
By using this approach, we have identified two targeted
therapies that when combined effectively inhibit growth of
RAS-active cancer cells: gefitinib, which inhibits EGFR and
U0126, which inhibits MEK1/2. The use of U0126 has been at
the forefront of MEK inhibitor research with more than 2500
citations of its parent discovery publication. U0126 is highly
selective, with a nanomolar specificity for MEK1/2, and
recorded off-target effects when concentrations greater than
10 mM are used (Favata et al., 1998), which is greater than the
dose used in our biochemical analyses. Moreover, U0126
shares similar inhibitory characteristics and functions as the
recently FDA-approved MEK inhibitor, trametinib (United
States Food and Drug Administration, 2013b; Yoshida et al.,
2012), potentially extending our observation to the clinic.
Indeed, we observe that using the FDA-approved EGFR and
MEK1/2 inhibitors erlotinib and trametinib in combination led
to similar results, lending support to the clinical relevancy
and feasibility of this treatment against RAS-active NSCLC
(Figure 6).
EGFR þMEK dual inhibition blocks two arms of the growth
factor receptor network in RAS-active NSCLC tumor cells:
EGFR-RAS-RAF-ERK and EGFR-PI3K-AKT-RPS6, whereas either
agent alone failed to achieve this multi-pathway inhibition ef-
fect. Of note, KRAS mutation status alone did not predict
response to this drug regimen; our analysis provides evidence
Table 2 eMultivariate predictors of GefitinibD U0126 response
(log10 EC50). Given that the dataset consisted of 39 cell lines, the
univariate analysis done previously was used to determine the set of
predictor variables that were individually significantly related to
GefitinibD U0126 response (log10 EC50). These variables were
included in the multivariate analysis. The multivariate analysis was a
linear model. Multivariate analysis determined the RAS-pathway






(Intercept) 1.1743 0.2027 5.793 0.0000014
RAS-Pathway
Activity Prediction
�1.0184 0.2933 �3.472 0.00139
Subtype: Large
cell carcinoma
0.2626 0.2321 1.130 0.27
Subtype: Squamous
cell carcinoma
0.2263 0.2230 1.015 0.32
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that some lung cancer cell lines with wild-type KRAS exhibit
high RAS-pathway activity. This is in line with observations
published by Molina-Arcas et al. (2013) that highlighted the
IGFR-centric nature of mutant KRASdbut not wild-type
KRASdlung cancer, in activating the PI3K-AKT-RPS6 node of
the pathway, with a strong implication of significant input
from EGFR in the wild-type KRAS cells. We observed that
best responders to EGFR þ MEK inhibition were wild-type
KRAS lung cancer cell lines with an activated RAS pathway.
This result may explain why the response to EGFR þ MEK in-
hibition correlates better to RAS-pathway activity than IGFR
and MEK inhibition (Figure 2C).
By studying RAS network activation through the genomics-
based biomarker, we have observed the requirement of
EGFR þ MEK signaling in maintaining activation of the PI3K-





















































































































H358 - MSO H358 - Gefitinib H358 – 0126 H358 – Gefitinib + U0126
H522 - DMSO H522 - Gefitinib H522 – U0126 H522 – Gefitinib + U0126
Figure 4 e EGFR D MEK combinatorial inhibition induces apoptosis in RAS-active, but not RAS-inactive tumor cells. (A) 3 RAS-active cell
lines, H358, Calu-3 and H2122 were treated with 1 mM of gefitinib, U0126 and gefitinibD U0126 as well as DMSO control for 72 h, and stained
for Annexin V. The percentage of Annexin V positive cells was calculated, averaged, and plotted, with the error bars indicating SEM. Only the
combined treatment of gefitinibD U0126 significantly induces apoptosis. (B) 3 RAS-inactive cell lines, H661, H520 and H522 were treated with
1 mM of gefitinib, U0126 and Gefitinib D U0126 as well as DMSO control for 72 h, and stained for Annexin V. The percentage of Annexin V
positive cells was calculated, averaged, and plotted, with the error bars indicating SEM. Neither treatment induces apoptosis. (C) Contour plots of
Annexin V/Propidium Iodide (PI) staining for RAS-active H358 cell line and (D) RAS-inactive cell line H522. The x-axis indicates Annexin V
staining, while the y-axis indicated PI staining. The lower right part of the graph shows the percentage of cells in early-stage apoptosis (Annexin V
positive cells), the top right the percentage of cells in late-stage apoptosis (Annexin VD PI double positive cells). The top left shows necrotic cells
(PI positive cells), while the bottom right shows live cells. Apoptosis is only induced in the RAS-active cell line.
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NSCLC. Interestingly, combinatorial inhibition of EGFR with
other components of the growth factor receptor network,
such as RAF or mTOR, does not correlate to RAS activity in
lung cancer cells. One reason the RAF inhibitor sorafenib is
not equivalent to MEK inhibition could be due to sorafenib’s
inability to block ERK signaling in KRAS-mutant cells
(Takezawa et al., 2009; Wilhelm et al., 2004). Together, these
studies highlight the complexity of RAS-centric signaling in
cancer, and the need to identify an appropriate target popula-
tion prior to initiation of clinical trials, as data suggests that
the different growth factor receptor network combinatorial
treatments will be effective only in discrete patient
populations.
Although clinical trials, such as the IPASS trial (Mok et al.,
2009) have shown efficacy of anti-EGFR tyrosine kinase inhib-
itors in EGFR-mutant NSCLC, inhibition of growth factor re-
ceptors has also been effective in unselected second-line
patients. For example, inhibition by anti-EGFR antibody cetux-
imab was beneficial in EGFR-positive patients in the FLEX and
IPASS trials (Mok et al., 2009; Pirker et al., 2009). Indeed, in
contrast to colon cancer, KRASmutations do not predict resis-
tance to EGFR inhibition in lung cancer (Guan et al., 2013;
Krejci et al., 2011; Mazzoni et al., 2011; O’Byrne et al., 2011).
While not nearly as effective as the gefitinib/U0126 combina-
tion, we do see some efficacy of gefitinib alone in our panel
of lung cancer cell lines. However, upon investigation of the
mechanisms by which these drugs function, we find that
EGFR antagonism alone does not significantly block down-
stream growth factor receptor network components such as
RAF, ERK and RPS6. Alternatively, MEK1/2 inhibition does
effectively inhibit ERK activity, but often fails to inhibit
alternative upstream EGFR signaling components such as
RAS and AKT. Only by combined treatment of both
EGFR þ MEK1/2 do we see effective inhibition of both up and
downstream growth factor receptor network components.
As ERK inhibition is a key regulator of proliferation and sur-
vival of cancer cells (Wortzel and Seger, 2011), and RPS6 also
plays vital roles important in cell survival as well as transla-
tion initiation (Ruvinsky and Meyuhas, 2006), we expect that
effectively blocking these two pathways in cancer cells con-
tributes to their synergistic function and decreased cancer
cell growth.
Interestingly, although RAS-inactive cell line H520 displays
synergy between gefitinib and U0126 (Supplementary
Figure 6A), the cell line still remains significantly recalcitrant
to the treatment, requiring a combinatorial EC50 dose of
11.27 mM, more than 4-fold less responsive than the average
response in RAS-active cell lines (EC50 ¼ 2.7 mM)
(Supplementary Figure 2B and Table 1). This is also the case
for the RAS-inactive cell line H661. Although it displays similar
overall pharmacodynamic pattern of pathway component in-
hibition as RAS-active cell lineswhen treatedwith gefitinib and
U0126, this cell line is also not comparatively sensitive to the
treatment (EC50 ¼ 10.28 mM). The observed synergy for these
lines is an interesting area for future mechanistic studies.
However, our conclusion that RAS-active cell lines are sensi-
tive to combined EGFR/MEK inhibition remains accurate.
Indeed, the RAS-inactive cell lines H520 and H661 are not sen-
sitive to this combined treatment (Supplementary Table 1), in-
dependent of their synergy profiles (Figure 3C, Supplementary
Figure 6A).
It will be critical in future clinical trials to identify those tu-
mors that are RAS-active independent of the mechanism of
RAS activation in order to best treat those patients with a
drug regimen that effectively blocks these key nodes in the
RAS pathway. By using mutation analysis alone, one over-
looks a large population of tumors that do not carry particular
mutations yet harbor activated oncogenic pathways. There
are currently clinical trials such as recruiting patients for
EGFR þMEK inhibitor combinations based onmutation status
alone. Our results suggest that mutation status alone cannot
always provide optimal selection of responsive patients. By
more comprehensively characterizing patients with dysregu-
lated pathway independent of the mechanism of activation,
it may be possible to better select patients for clinical trial
inclusion.
Gene-expression signatures have recently made their way
to the clinical and commercial sectors, laying the foundation
for the feasibility of bringing any future gene-expression sig-
natures to the clinic (Arpino et al., 2013). One example is the
FDA-approved microarray-based gene-expression profiling
signature Mammaprint which uses tissue core sampled on
fresh specimens preserved in RNA later or frozen archived tis-
sue as sourcematerial, to output and score low/high risk of tu-
mor metastasis (Arpino et al., 2013; van ’t Veer et al., 2002; van
de Vijver et al., 2002). Therefore, the application of a gene-
expression signature as a genomic biomarker of RAS-pathway
activation is both promising and feasible.
Overall, our data shows the significant correlation between
RAS-pathway activity and response to EGFR þMEK inhibition
(Figure 2A and B), and the predictive power of our signature
Figure 5 e The EGFR pathway and the model of the effect of EGFR/
MEK/EGFR D MEK inhibition on the pathway in RAS-active
NSCLC cell lines. EGFR monotherapy inhibits activation of EGFR,
KRAS and AKT (blue), while U0126 inhibits the activity of MEK,
preventing the activation of ERK (red). Combined therapy leads to
the inhibition of all the aforementioned proteins (blue and red) plus
RPS6 and RAF1 (purple), which are also degraded.
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which is independent of other factors such as cancer subtype
of mutations in key pathway components (Tables 1 and 2). In
the clinic, the RAS gene-expression signature could be used to
assess RAS-pathway activation status in a patient’s tumor. If
the tumor has high pathway activity, that patient may be a
candidate to receive EGFR þ MEK dual inhibition. Indeed, the
clinical potential of our study is supported by the validation
of our observed correlation of RAS-pathway activation and
EGFR þ MEK dual inhibition using FDA-approved inhibitors
(Figure 6).
Lastly, it is important to note that while tumor heterogene-
ity will ultimately be important in identifying and treating re-
fractory subclones within a tumor, our current approach is to
analyze the overall RAS activity within a tumor. Thus, higher
levels of RAS activity within a tumor will predict greater
overall response. Arguably, our approachmeasures RAS activ-
ity within the bulk tumor, where there may be subclones that
are a minority population but still have varied RAS activity.
Current and future studies are dedicated to addressing this
ongoing issue in tumor characterization and treatment.
In summary, we described a genomic-based screen that
characterizes RAS-pathway activation and identifies drugs
that effectively target the pathway, inducing an apoptotic tu-
mor cell response. By using a genomic approach to charac-
terize oncogenic pathway activity in tumor cells, the ability
to find drugs that target and inhibit a specific pathway is
increased. Given the complexity and crosstalk of signaling
pathways that is unique to individual tumor phenotypes, it
is essential to identify and block the relevant pathway compo-
nents for optimal drug response. By applying a genomic













































































































































Figure 6 e Combinatorial inhibition of EGFR D MEK using FDA-approved inhibitors is correlated to RAS-pathway activity in NSCLC. (A)
Linear correlation of erlotinib D trametinib EC50 values with the predicted probability of RAS-pathway activation across 16 NSCLC cell lines.
Response to erlotinibD trametinib is significantly negatively correlated to RAS. Legend[ Red: KRAS-mutant cell lines, Black: KRAS wild-type
cell lines. (B) Cell lines of the 16 NSCLC panel were divided accordingly and box plot diagrams of erlotinibD trametinib EC50 values were plotted.
Response to erlotinib D trametinib as measured by EC50 values is shown. Cell lines with elevated probability of RAS activation (predicted
probability of RAS-pathway activation> 0.5) were significantly more sensitive to erlotinib D trametinib treatment than cell lines with low
probability of RAS activation (predicted probability of RAS-pathway activation< 0.5). (C) Response to erlotinibD trametinib with respect to the
mutation status of KRAS, as measured by EC50 values. K-RAS mutation does not predict response to erlotinib D trametinib.
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approach to discovery of pathway-specific drug regimens, we
can identify the patients who may best benefit from those
treatment regimens prior to initiation of a clinical trial.
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Cell Line G+U EC50 (Log10) RAS Subtype K-Ras Mut P53 Mut MEK1 Mut EGFR Mut
97TM1 0.6524 0.9136026 L G12V P34fs FRAME SHIFT DEL x x
A549 0.9266 0.6067645 A G12S x x x
CALU3 -0.5487 0.8306487 A x M237I x x
H1155 1.241 0.0945059 L Q61H R273H ND x
H1355 0.7158 0.677792 A G13C E285K x Q1159H
H1373 0.9067 0.9139701 A G12C E339* x Intron
H1395 1.471 0.4569164 A x x ND x
H1437 0.6694 0.6525064 A x R267P Q56P x
H1563 0.6503 0.3695481 A x x x x
H1581 1.124 0.0405064 L x Q144* x x
H1650 0.5016 0.6184945 A x V225_splice x ELREA746del
H1651 1.012 0.3080696 A x C176Y x x
H1693 0.9227 0.3260345 A x Q331_splice x x
H1703 1.011 0.2062118 A x A307_splice x x
H1792 1.049 0.8125829 A G12C E224_splice x x
H1793 1.151 0.4864989 A x R209* x C311F
H1944 0.631 0.7229063 A G13D x 5'UTR INS x
H1975 0.485 0.7404292 A x x x T790M, L858R
H2009 0.8024 0.751463 A G12A R273L x Intron
H2030 0.01976 0.7927377 A G12C G262V x x
H2085 0.5938 0.6550824 A x ND ND ND
H2122 -0.1607 0.9452425 A G12C C176F, Q16L 5'UTR INS x
H2126 -0.1813 0.6254516 A x E62* x x
H2170 0.9238 0.5251964 S x R158G x x
H226 0.5961 0.6553798 S x x x x
H23 0.6753 0.7705322 A G12C M246I x x
H2405 0.5364 0.8837517 A x x x x
H322 0.009897 0.7698003 A x R248L ND x
H358 -0.1012 0.6174521 A G12C x x x
H441 0.3012 0.8120077 A G12V R158L x x
H460 1.257 0.6202589 L Q61H x Y134C x
H520 1.052 0.1024499 S x W146* x x
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H522 1.026 0.0699702 A x P191fs FRAME SHIFT DEL x x
H661 1.012 0.1929882 L x R158L, S215I x x
H838 0.6219 0.2447621 A x x x x
HCC4006 -0.9972 0.847452 A x x 5'UTR INS ELR746del INFRAME
SKLU1 0.7909 0.7119265 A G12D H193R x x
SKMES1 0.2849 0.870242 S x E298* x x
SW1573 1.621 0.3261704 S G12C Intron x x
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SUPPLEMENTARY MATERIALS AND METHODS 
Cell Lines and Media 
The lung cancer cell lines used in this study and their characteristics are summarized in 
Supplementary Table 1. Cancer cell lines were grown and maintained in a humidified 
environment at 37°C and 5% CO2 in their respective media (see below). For the preliminary 
genomics-based drug screen, 14 lung cancer cell lines were grown in 5% FBS (Gibco/Life 
technologies, Carlsbad, CA) and 1x Anti-Anti (Gibco/Life technologies, Carlsbad, CA) in their 
corresponding media, and plated 2000 cells/well onto 384-well plates. H838, H1563, A427, 
H1944, H2170, H520, HCC4006, H1650, H1975, H661 were grown in RPMI. H2126 was grown 
in HITES, A549 in F12K, SK-MES-1 in EMEM and H1581 in ACL-4. For the expanded drug 
screen, the following 39 NSCLC cell lines were used for the novel compound drug screen as 
well as to generate dose response curves for gefitinib, sorafenib, U0126 and their dual 
combinations: H1155, H1355, H1581, H2085, H2405 and H1651 were grown in ACL-4; Calu-3, 
LCLC-97TM1,  SK-LU-1 and SK-MES-1 were grown in EMEM; A549 in F12K; H1793, H2009 
and H2126 were grown in HITES; SW1573 was grown in DMEM; H1373, H1437, H1395, 
H2170, H1650, H226, H1563, H1703, H1792, H1944, H1975, H2030, H2122, H23, H322, 
H358. H441, H460, H520, H522, H661, H838, HCC4006 and H1693 were grown in RPMI. The 
replicate screen was performed on 35 cell lines (adding H1648 grown in ACL-4, and excluding 
97TM1, H226, H1395, H2170, H1650 due to an insufficient number of cells). For the 16 lung 
cancer cell line dose response assay for erlotinib+trametinib, the following cell lines were used 
in their media as described above: H1155, H1650, H1792, H2030, H441, SW1573, Calu-3, 
H1355, H1703, H2405, H322, H520, H522, H661, SK-MES-1, and H2170. For the breast cancer 
cell line screen, the following 35 cell lines were used: AU565, BT20, BT474, BT483, BT549, 
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CAMA-1, HCC1143, HCC1395, HCC1419, HCC1500, HCC1569, HCC1599, HCC1806, 
HCC1937, HCC1954, HCC2218, HCC38, HCC70, Hs343T, JMT-1, MCF-7, MDAMB134-VI, 
MDAMB157, MDAMB175-VII, MDAMB231, MDAMB361, MDAMB415, MDAMB436, 
MDAMB453, MDAMB468, SKBR3, T47D, UHCC812, ZR-75-1, ZR-75-30. Breast cancer cell 
lines were grown according to the media recommended by ATCC and in 5% FBS and 1x Anti-
Anti (Gibco).  
Breast Cancer Cell Line Dose Response Assay 
For the breast cancer cell line screen, and the 35 NSCLC screen, cells were plated at 1500 
cells/well. For the dose response assays, known targeted therapeutics were serially diluted 1:3 
from 30µM to the lowest dose of 13.72nM in media containing 5% FBS (Gibco) and 1x Anti-
Anti (Gibco). To make the highest dose soluble in aqueous media, drugs were sonicated twice on 
ice. For combination treatments, doses had equal molar concentrations for each compound. Dose 
response curves were generated using the same methodology described in the body of the paper, 
methods section. 
Cell Lysis and Western Blotting 
Cell lines were washed once in ice-cold PBS then lysed in buffer containing 1% Triton 
X-100, 50mM HEPES, pH 7.4, 150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 
10mM Na pyrophosphate, 1mM Na3VO4, 10% glycerol, and protease inhibitors (P8340) added 
fresh from Sigma-Aldrich (St Louis, Missouri). Lysates were incubated on ice for 15 minutes, 
then centrifuged at 14,000 RPMs in 4’C. Protein yield was analyzed using the Bradford reagent 
(Amresco, Solon, OH). Equivalent amounts of protein were resolved on 12% precast SDS-PAGE 
gels (Biorad, Hercules, CA) and transferred to Immobilon-P PVDF membranes (Millipore, 
Billerica, MA). IgG HRP-linked Secondary antibodies were used from GE Lifesciences 
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(Pittsburgh, PA). Western blots were developed using SuperSignal West Dura Substrate 
(Thermoscientific, Rockford, IL). 
 
Synergy Calculation 
The expected effects for each combinatorial therapy dose were calculated using the Bliss 
Independence method utilizing the following formula: Expected effect of dose A = (Drug1 dose 
A + Drug2 dose A) – (Drug1 dose A * Drug2 dose A) (Buck et al, 2006; Fitzgerald et al, 2006). 
Theoretical effect dose response curves were plotted for the 39 cell lines for gefitinib+U0126, 
sorafenib+U0126 and gefitinib+U0126 using these expected dose values, and the theoretical 
EC50 values computed using GraphPad Prism as described before. To determine synergy, the 
theoretical EC50 values were divided by the actual EC50 values; values greater than one 
signified synergy, values equal to one signified additivity, and values less than one indicated 
antagonism (Soldi et al, 2013). 
 
SUPPLEMENTARY FIGURE AND TABLE LEGENDS 
Supplementary Figure 1: Preliminary screen reveals a strong correlation between the 
response to dual suppression of EGFR and MEK and RAS pathway activation. EC50 values 
of Gefitinib, U0126 and Gefitinib+U0126 were calculated for a pilot panel of 14 NSCLC cell 
lines. The predicted probability of RAS pathway activation of these cell lines was also obtained 
using our RAS gene expression signature. These 2 values were plotted on a dot plot, and the 
linear correlation between the two investigated. Every dot represents a cell line, with a y value 
representing the line’s treatment EC50 (log10), and an x value representing the cell lines 
predicted probability of RAS pathway activation score. (A) Linear correlation of 
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Gefitinib+U0126 EC50 values with the predicted probability scores of the 14 cell lines. (B) 
Linear correlation of U0126 with predicted probability of RAS pathway activation (C) Linear 
correlation of Gefitinib with predicted probability of RAS pathway activation. Legend: Red: 
KRAS mutant cell lines, Black: KRAS wild type cell lines 
 
Supplementary Figure 2: Preliminary screen reveals the response to mTOR suppression, 
alone or in combination with EGFR and MEK inhibition does not correlate to RAS 
pathway activation. (A) Linear correlation of Gefitinib+U0126 EC50 values with the predicted 
probability scores of the 14 cell lines. (B) Linear correlation of U0126 with predicted probability 
of RAS pathway activation (C) Linear correlation of Gefitinib with predicted probability of RAS 
pathway activation. Legend: Red: KRAS mutant cell lines, Black: KRAS wild type cell lines 
 
Supplementary Figure 3: The response to combinatorial inhibition of EGFR and MEK, but 
not the monotherapy is correlated to RAS pathway activity in NSCLC. (A) Treatment of 
Gefitinib+U0126 on an expanded panel of NSCLC cell lines was repeated in a second time, with 
nearly identical results. Linear correlation of Gefitinib+U0126 EC50 values with the predicted 
probability of RAS pathway activation across 35 NSCLC cell lines. (B) The EC50 values of the 
top 50% most responsive cell lines for each treatment were averaged out and graphed into box 
plots. Box boundaries denote the 25th-75th percentiles, while the error bars indicate maximum 
and minimum values. The line inside the box indicates the median value, and the “+” indicates 
the mean value. (C) Linear correlation plot of Gefitinib across 39 NSCLC cell lines (D) Linear 
correlation plot of U0126 across 39 NSCLC cell lines. Legend: Red: KRAS mutant cell lines, 
Black: KRAS wild type cell lines 
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Supplementary Figure 4: Response to RAF inhibition is not correlated to RAS pathway 
activation, regardless of combinatorial inhibition of MEK and EGFR. Linear correlation plot 
of Calculated EC50 values of response of the 39 cell lines and their predicted probability of RAS 
activation scores were plotted on for (A) Sorafenib, (B) Sorafenib+U0126, (C) 
Sorafenib+Gefitinib. Legend: Red: KRAS mutant cell lines, Black: KRAS wild type cell lines 
 
Supplementary Figure 5: Combinatorial Inhibition of EGFR and MEK is an efficacious 
and synergistic therapy in NSCLC. (A) Dose response assay curves of 3 of the top 4 
synergistic cell lines in our panel. Green shows the theoretical curve that would result from the 
additivity effect of combining Gefitinib and U0126, the black curve indicates the actual effect 
observed from the combinatorial therapy. (B) EC50 values of the single agent treatment of 
Gefitinib and U0126 and the combinatorial therapy across all the 39 NSCLC cell lines are plotted 
as boxplots. (C) Dose response curves using the dose means of all the 39 cell lines of Gefitinib, 
U0126, and Gefitinib+U0126. 
 
Supplementary Figure 6: Combinatorial Inhibition of RAF with EGFR or MEK is 
minimally synergistic, while EGFR and MEK dual inhibition is largely synergistic in 
NSCLC. (A) Synergy scores of Gefitinib+U0126 Combinatorial treatment across the panel of 39 
NSCLC cell lines. Synergy was investigated by calculating the theoretical EC50 of the combined 
treatment, and dividing it by the experimental EC50. Scores >1 (columns above the red line) 
indicate a synergistic relationship between Gefitinib and U0126 in killing NSCLC tumor cells. 
Scores <1 indicated drug antagonism, and scores = 1 indicates drug additivity. A total of 29/39 
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cell lines (74%) of cell lines showed synergy for the combinatorial treatment. (B) A total of 
13/39 cell lines (33%) of cell lines showed synergy for Sorafenib+Gefitinib combinatorial 
treatment. (C) Synergy scores of Sorafenib+U0126 combinatorial treatment across the panel of 
39 NSCLC cell lines. 26/39 cell lines (67%) showed synergy for the combinatorial treatment, 
although the synergy scores were much smaller than Gefitinib+U0126. (D) EC50 values of 
Sorafenib, Sorafenib+Gefitinib and Sorafenib+U0126 across all the 39 NSCLC cell lines are 
plotted as boxplots 
 
Supplementary Figure 7: EGFR+MEK inhibition is unskewed by the 8 most correlative 
cell lines and is not correlated to RAS pathway activation in Breast Cancer. (A) The graph 
shows the linear correlation of Gefitinib+U0126 with the predicted probability of RAS pathway 
activation across the same panel of NSCLC cell lines in Figure 2A, with the 8 most correlative 
cell lines taken out. (B) The graph shows the linear correlation of Gefitinib+U0126 with the 
predicted probability of RAS pathway activation across the 35 breast cancer cell lines. Red: 
KRAS mutant cell lines, Black: KRAS wild type cell lines. 
 
Supplementary Figure 8: The RAS Gene expression signature and KRAS mutation do not 
predict response to Sorafenib, U0126 or Gefitinib in NSCLC. Cell lines of the 39 NSCLC 
panel were divided accordingly and Boxplot diagrams of Gefitnib+U0126 and 
Gefitinib+Sorafenib and EC50 values plotted. (A) Response to Sorafenib with respect to the 
predicted probability of RAS pathway activation, as measured by EC50 values. (B) Response to 
Sorafenib with respect to the mutation status of KRAS, as measured by EC50 values. (C) 
Response to Sorafenib with respect to mutation status of KRAS, and predicted probability of 
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RAS pathway activation. (D) Response to Gefitinib with respect to the predicted probability of 
RAS pathway activation, as measured by EC50 values. (E) Response to Gefitinib with respect to 
the mutation status of KRAS, as measured by EC50 values. (F) Response to Gefitinib with 
respect to mutation status of KRAS, and predicted probability of RAS pathway activation. (G) 
Response to U0126 with respect to the predicted probability of RAS pathway activation, as 
measured by EC50 values. (H) Response to U0126 with respect to the mutation status of KRAS, 
as measured by EC50 values. (I) Response to U0126 with respect to mutation status of KRAS 
and predicted probability of RAS pathway activation, as measured by EC50 values. 
 
Supplementary Figure 9: The RAS Gene expression signature and KRAS mutation do not 
predict response to sorafenib+U0126 or sorafenib+gefitinib in NSCLC. Cell lines of the 39 
NSCLC panel were divided accordingly and Box plot diagrams of Gefitnib+U0126 and 
Gefitinib+Sorafenib and EC50 values plotted. (A) Response to Sorafenib+U0126 with respect to 
the predicted probability of RAS pathway activation, as measured by EC50 values. (B) Response 
to Sorafenib+U0126 with respect to the mutation status of KRAS, as measured by EC50 values. 
(C) Response to Sorafenib+U0126 with respect to mutation status of KRAS, and predicted 
probability of RAS pathway activation. (D) Response to Gefitinib+Sorafenib with respect to the 
predicted probability of RAS pathway activation, as measured by EC50 values. (E) Response to 
Gefitinib+Sorafenib with respect to the mutation status of KRAS, as measured by EC50 values. 
(F) Response to Gefitinib+Sorafenib with respect to mutation status of KRAS, and predicted 
probability of RAS pathway activation.  
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Supplementary Figure 10: Box plots of the predicted probability of RAS pathway 
activation in the panel of 39 NSCLC cell lines and the overall EC50 response to EGFR and 
MEK inhibition based on subtype. Cell lines were divided according to their specified NSCLC 
subtype, and their (A) probability of RAS pathway activation scores (B) Gefitinib+U0126 EC50 
scores grouped together. Adenocarcinomas had the highest predicted probability of RAS 
pathway activation and sensitivity to Gefitinib+U0126. 
 
Supplementary Figure 11: Further effects of gefitinib, U0126 and gefitinib+U0126 on the 
EGFR pathway and RAS protein activation. (A) The effects of the aforementioned treatments 
were further investigated on more components of the EGFR and RAS pathways through western 
blotting.  (B) Activated KRAS (KRAS GTP) was pulled down and blotted for after cell line 
treatment of gefitinib, U0126, gefitinib+U0126 at 5µM dose for 6hrs. GAPDH was blotted for on 
the same lysates to test for equal loading. Only gefitinib inhibits the activation of KRAS in 2/3 
cell lines 
 
Supplementary Table 1: Characteristics of the 39 NSCLC cell lines used in the study. “G+U 
EC50 (log10)” denotes the calculated EC50 dose of Gefitinib+U0126 in log scale. “RAS” 
column denotes predicted probabilities of RAS pathway activation among the cell lines. “. “A” 
denotes the NSCLC Adenocarcinoma subtype, “S” denotes squamous cell carcinoma, and “L” 
denotes large cell carcinoma. The rest of the columns highlight the specific amino acid mutations 
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3.1  Abstract
Patients diagnosed with Basal-like or Claudin-low breast cancer (BL-CL) 
suffer from a poor prognosis and limited treatment options. To identify compounds 
with potential therapeutic efficacy, we used a step-wise screening approach 
personalized for the identification of a compound effective against BL-CL. We 
screened 2778 HP20 fractions from our marine invertebrate compound library 
(MICL) and identified a previously unreported trisulfated sterol, topsentinol L 
trisulfate (TLT) that exhibits increased efficacy against BL-CL relative to Luminal/
HER2+ breast cancer. Biochemical investigation of the effects of TLT on BL-CL 
revealed its ability to inhibit activation of AMPK and CHK1. The importance of 
targeting these two proteins in BL-CL was validated by treating a panel of breast 
cancer cell lines with known small molecule inhibitors of AMPK and CHK1 and 
recording the increased effectiveness against BL-CL compared to Luminal/
HER2+ breast cancer. Finally, we generated a TLT sensitivity gene-expression 
signature and projected it against a human tumor panel of 12 different cancer 
types and identified breast and bladder cancer as the cancers most sensitive to 
TLT. Conversely, glioblastoma multiforme was projected to be least sensitive to 
TLT. These results identify TLT, a previously uncharacterized trisulfated sterol, as 
a potential therapeutic selective against BL-CL. The mechanistic treatment effects 
of TLT are described, proposing the potential of AMPK and/or CHK1 inhibition as 
an effective therapy in BL-CL.
3.2  Introduction
Gene-expression profiling has identified five molecular subtypes of breast 
cancer, known as Luminal A, Luminal B, HER2-enriched, Claudin-low and Basal-
like, with inter-subtype differences in incidence, survival and treatment response 
[1-5]. Among these, breast cancer patients diagnosed with the Claudin-low and 
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Basal-like molecular subtypes exhibit particularly poor prognosis and suffer from 
limited treatment options [6].  Basal-like breast cancers represent 10-25% of all 
breast carcinomas, generally occurring at an early age, with higher frequency in 
women of African origin [7]. Approximately 50%-70% of all basal-like cancers lack 
the expression of ER, PR and HER2 and are therefore clinically described as being 
triple negative. Basal-like breast cancer manifests as a highly aggressive tumor 
that is responsive to chemotherapy [6]. However, patient prognosis remains poor 
with Basal-like cancers exhibiting a high recurrence rate and low patient survival 
[2]. At the molecular level, Basal-like breast cancers exhibit expression patterns 
as also observed in the basal epithelial layer of the skin and airways; this includes 
expression of high molecular weight cytokeratins 5, 6 and 17 and deficiencies in 
RB1, BRCA1 and TP53. Moreover, a high rate of aneuploidy is observed in these 
tumors, reflective of increased genetic instability [6,7].
Interestingly, the Claudin-low group shares some similarities in gene-
expression features with the Basal-like subtype such as low expression of HER2 
and the luminal gene clusters, indicating genomic similarities between the two 
groups [8]. Moreover, like the Basal-like subtype, Claudin-low tumors are also 
triple negative and have a poor prognostic outcome.  However, Claudin-low 
breast cancers remain an individual group on their own, characterized by the 
minimal expression of several claudin genes, such as claudin 3, 4 and 7, which 
are involved in epithelial cell tight-tight junctions. These tumors also lack cell–
cell junction proteins, such as E-cadherin, and almost always are characterized 
by having an intense immune cell infiltrate, stem cell properties, and features 
of epithelial–mesenchymal transition (EMT) [3,4,7,9,10]. Due to the nonluminal 
molecular nature of these two subtypes, and the lack of known protein targets on 
these cancers, few effective treatment options are available. As such, there exists 
an urgent need to identify new therapeutic leads and potential targets that can 
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improve patient prognosis. 
 To identify a novel compound effective against Basal-like and Claudin-
low breast cancer (BL-CL), we screened a subset of our unique library of marine 
invertebrate compounds against a large panel of cancer cell lines. The Marine 
Invertebrate Compound Library (MICL) is a unique resource that serves as a 
platform for discovery of novel small molecule-mediated biological activities in 
a variety of systems. MICL is derived from an extensive collection of over 1200 
unique marine organisms (85% sponges from over 150 genera, 12% tunicates, 
2% other phyla) collected from diverse locations around the world over the past 20 
years [11,12]. Around 75% of all anticancer drugs developed between 1940 and 
2010 were either derived from or inspired by natural products [13]. As of 2010, 
there were 13 marine natural products (MNPs) in clinical trials, ten of which target 
cancers [14]. Natural products tend to be more complementary in shape to their 
targets [15] due to their development in a competitive ecological selection process 
that favors the production of compounds with strong biological activity [16-18]. 
Several marine natural products in particular have been shown to exhibit anti-
cancer properties, such as didemnin B, aplidine and ecteinascidin-743, the latter 
of which succeeded in passing clinical trials in Europe and is now approved by the 
European Commission for the treatment of refractory soft-tissue sarcomas [19]. In 
summary, MNPs have proven their potential for development into clinically-useful 
drugs [14,19]. 
In this study, we screened 2778 fractions from MICL with the goal of 
identifying a candidate fraction with anti-BL-CL activity and isolating the active 
compound responsible for such a property. To accomplish this goal, we first 
identified the fractions that exhibited anticancer activity by screening against a 
panel of cancer cell lines. These anticancer fractions were then used in a second 
screen to identify those with selectivity against BL-CL. The unique compounds in 
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each were isolated and validated for BL-CL activity, leading to the identification of a 
candidate compound. We identified a previously uncharacterized trisulfated sterol, 
topsentinol L trisulfate (TLT), purified from a marine sponge Topsentia sp. (PNG07-
3-073) collected from Papua New Guinea. TLT, as well as its parent fraction and 
subfraction, exhibited increased effectiveness against BL-CL compared to Luminal 
and HER2+ subtypes. We showed that treating BL-CL cell lines with TLT leads 
to the inhibition of AMPK and CHK1 using biochemical and proteomic analyses. 
To validate the importance of inhibiting the activity of AMPK/CHK1 in BL-CL, we 
tested breast cancer cell lines with known small molecule inhibitors of AMPK and 
CHK1, and observed that they are significantly more effective against BL-CL than 
Luminal and HER2+ subtypes. This study was concluded by generating a genomic 
gene-expression signature of TLT sensitivity and projecting it against a panel of 
human patient tumors of 12 different cancer types, identifying breast and bladder 
cancer as the two cancers most sensitive to TLT. Overall, this study incorporates 
the genomic classification of breast cancer to high-throughput drug screening and 
identifies a novel small molecule, TLT, personalized against BL-CL. Furthermore, 
the work described here sheds light on the importance of targeting AMPK and/or 
CHK1 in this molecular subtype, and suggests the potential of these proteins as 
therapeutic targets in BL-CL.
3.3  Materials and Methods
3.3.1  Cell lines and Viability Measurement
Cell lines were obtained from ATCC and plated at 1500-2000 cells/well in 
384-well plates in 5% FBS (Gibco/Life Technologies, Carlsbad, CA) growth media 
and 1x Anti-Anti (Gibco/Life Technologies, Carlsbad, CA). Cancer cell lines were 
cultured and maintained in a humidified environment at 37 °C and 5% CO2 in 
their respective media. Detailed description on the cell lines used for each screen 
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is available in Supplementary Tables 3.1 and 3.2. Cells were treated for 72 hrs, 
after which cell viability and growth were measured using CellTiter-Glo (Promega, 
Madison, WI). Cell viability scores were calculated by dividing the viability scores 
of the treatment by the control DMSO values.
3.3.2  Small Molecules
Dorsomorphin C and Ly2603618 were purchased from Selleckchem and 
dissolved in water and 100% DMSO, respectively. Dorsomorphin C was prepared 
as a stock of 100 mM, while Ly2603618 was prepared as a 28.65 mM stock.
3.3.3  MICL Screens 
For Screen 1, 2778 HP20 fractions of marine organisms from MICL were 
screened at a single dose (~1.5 µM) against a panel of 16 (9 lung and 7 breast) 
cancer cell lines to determine fractions with antitumor properties. One hundred and 
seven HP20 fractions were chosen according to the following selection criteria: 
1) all fractions with a standard deviation in viability of greater than 0.325; 2) Lung 
selective fractions (25% or less viable cells in three or more lung cancer cell lines 
and two or fewer breast cancer cell lines);  3) breast selective fractions (25% or 
less viable cells after treatment in two or more breast cancer cell lines and three 
or fewer lung cancer cell lines); 4) generally active nonuniversally toxic fractions 
(25% or less viability in a minimum of 5 and maximum of 13 cell lines); 5) relatively 
less active fractions (40% or less viability in a minimum of 9 and maximum of 13 
cell lines). An additional 85 HP20 fractions from MICL that were not screened for 
were added to the selected 107 fractions based on chemo-taxonomic judgment 
of potential chemical similarity to the 107 fractions. These 192 HP20 fractions 
were then subjected to a second screening assayed at a single dose (~1.5 µM) 
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against a panel of 35 breast cancer and 37 lung cancer cell lines. This identified 
breast-selective fractions (fractions resulting in 25% or less cellular viability after 
treatment in 13 cell lines or more out of 35 breast cancer cell lines, and 12 cell 
lines or fewer lung cancer cell lines) and fractions effective against BL-CL (BL-
CL vs Luminal/HER2+ breast cancer unpaired two-sample equal variance t-test 
< 0.05 with a positive average difference). Cell lines described as basal-like or 
claudin-low but being HER2+ were considered part of the Luminal/HER2+ group. 
LCMS (liquid crystal-mass spectroscopy) fractionation of the anti-BL-CL fractions 
following the MICL protocol [11,12] resulted in 20 subfractions each that were 
assayed for effectiveness against BL-CL in a panel of 33 breast cancer cell lines. 
Once a candidate subfraction was determined based on the results of all three 
screens, large scale isolation and the purification of the active compound of that 
fraction was pursued
3.3.4  Large-scale Isolation and Purification of  
Active Compound
Frozen PNG07-3-073 Topsentia sp. sponge (215 g, Supplementary Figure 
3.1) was extracted three times with methanol. One half of the pooled methanol 
extract was fractionated on Diaion HP20SS resin, eluting with water/isopropanol 
mixtures in 25% increments, followed by 100% methanol to yield five fractions, FW 
and F1-F4, where F2 was the only fraction that exhibited tumoricidal properties. 
F2 (50/50 IPA/H2O, 98 mg) was subjected to C18 flash chromatography, eluting 
with 40-100% methanol in water in 10% increments, yielding 46 subfractions, of 
which only subfractions 22, 23, 24 and 25 showed tumoricidal activity. Bioactive 
fractions 22-25 were combined (65 mg) and further fractionated by HPLC using 
a Luna 5 µm phenylhexyl column (250 x 4.6 mm) and a gradient of acetonitrile 
(ACN) with 0.2 M NaCl (36% ACN increasing over 4 min to 43% ACN, held for 
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11 min, then decreased to 36% ACN over 2 min) to yield isolate 1 (sharp peak, 
RT=9.57 min, 13.4mg) and isolate 2 (broad peak, RT=10.2 min, 6.3mg). Salt was 
removed by loading samples onto pre-equilibrated Waters Sep-Pak C18 cartridges 
and flushing with three column volumes of 10% methanol, followed by compound 
elution with 100% methanol. 
3.3.5   Dose Response Assays
Cell lines were plated as described above. Dorsomorphin C and Ly2603618 
were serially diluted 1:3 starting from 90 µM to the lowest dose of 41.15 nM in RPMI 
media containing 5% FBS and 1x Anti-Anti and screened against a panel of 20 cell 
lines, along with the combination treatment of dorsomorphin C and Ly2603618. 
For the combination treatment, an equal molar concentration of each compound 
was used. TLT was serially diluted 1:2 starting from 104.4 µM to the lowest dose of 
3.26 µM and screened against a panel of 30 cell lines. Cell viability was measured 
as described before. Doses were repeated in quadruplicates and averaged out for 
a single value. EC50 values were calculated from dose response curve data by 
plotting on GraphPad Prism 6.01 and using the equation Y=1/(1+10^((logEC50-
X)*HillSlope) with a variable slope (Ymin = 0 and Ymax = 1). Plots were forced to 
start from the x-axis by plotting for an x-intercept point. 
3.3.6  Cell Lysis and Western Blotting
Cell lines were washed once with ice-cold PBS (1x) and then lysed in a 
buffer containing 1% Triton X-100, 50mM HEPES, pH 7.4, 150mM NaCl, 1.5mM 
MgCl2, 1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM Na3VO4, 10% 
glycerol, and protease inhibitors (P8340) added fresh from Sigma-Aldrich (St Louis, 
Missouri).  Lysates were then incubated on ice for 15 min with agitation every 2 
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min, and then centrifuged at 14,000 RPMs in 4°C. Protein yield was quantified 
using the Bradford reagent (Amresco, Solon, OH) and denatured by boiling 
and SDS treatment (with beta-mercaptoethanol). Equivalent amounts of protein 
(approximately 30 µg) were resolved on 12% precast SDS-PAGE gels (Biorad, 
Hercules, CA) and transferred to Immun-blot PVDF membrane (Biorad, Hercules, 
CA). IgG HRP-linked Secondary antibodies were used from GE Lifesciences 
(Pittsburgh, PA). Western blots were developed using SuperSignal West Dura 
Substrate (Thermoscientific, Rockford, IL).
3.3.7   Immunostaining
Four BL-CL cell lines sensitive to topsentinol L trisulfate (HCC70, HCC1143, 
MDAMB468, MDAMB436) were treated with 105µM of TLT in 5% FBS RPMI media 
and 1x Anti-Anti for 6 hrs. Primary antibodies for GAPDH (#5174S), p38-T180/
Y182 (#4511S), pChk1-S317 (#12302) and pAMPKα-T172 (#2535) were obtained 
from Cell Signaling Technology (Beverly, MA).
3.3.8  Reverse Phase Protein Array
Eight TLT-sensitive BL-CL cell lines (MDAMB157, MDAMB436, MDAMB468, 
MDAMB231, HCC38, HCC70, HCC1395, and HCC1143) were treated separately 
with TLT or DMSO at a concentration of 105µM (approximate average EC75 across 
all eight cell lines) for 6 hrs, after which they were lysed according to methodology 
detailed in above. Reverse phase protein array was performed at the University 
of Texas MD Anderson Cancer Center by the functional proteomics RPPA core 
facility according to their described methods and protocol [20,21]. Two hundred 
seventeen different antibodies of phosphorylated and non-phosphorylated proteins 
were stained for and quantified.
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3.3.9  RNA Sequencing Data Acquisition 
The same eight TLT-sensitive BL-CL cell lines were treated separately with 
TLT or DMSO for 6 hrs, after which total RNA was extracted using the RNeasy Mini 
Kit (Qiagen, Venlo, Netherlands) with on-column digestion of the genomic DNA, 
as described in the manufacturer’s protocol. RNA sequencing was performed at 
the Huntsman Cancer Institute High Throughput Genomics Core Facility using 
50-cycle, single-read sequencing (version 3) on an Illumina HiSeq instrument. 
To construct mRNA focused libraries from total RNA, the Illumina TruSeq RNA 
Sample Prep Kit (version 2) with oligo dT selection was used. 
3.3.10  TLT Sensitivity Signature Generation and Analysis
To process the mRNA sequencing data, we used the TCGA mRNA-seq 
Pipeline [22]. RNA sequencing reads for the treated and control samples were aligned 
using MapSplice v12_07 [23], quantified using RSEM [24], and gene counts were 
normalized using upper quantile normalization. This was the same methodology 
used to normalize the PANCAN12 TCGA dataset, which we obtained from TCGA fully 
processed for use in this analysis [22]. To generate a TLT sensitivity signature, we 
used the DESeq2 package (version 1.4.5) in the Bioconductor framework (version 
2.14.0, version 3.1.0 of R) to identify genes that were significantly deregulated 
(adjusted p < 0.05) between the treated and control samples [25,26]. One hundred 
forty-six genes were found to be significantly deregulated, out of which only 131 
were found in the TCGA dataset. To use DEseq2, the reads had to be remapped 
using the Rsubread Bioconductor package. We used this package to map the 
reads to version hg19 of the human genome and to summarize the data to gene-
level values [27]. We predicted TLT sensitivity for the PANCAN12 TCGA dataset 
[22] using the Bayesian binary regression algorithm version 2.0 (BinReg2.0) used 
as a MATLAB plug-in [28]. We used default parameters, except that our signature 
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used 131 genes and 1 metagene. The probability output from the binary regression 
model was subtracted from one, so that probabilities closer to one indicated higher 
probability of sensitivity to the drug as previously described [29]. Prior to making the 
predictions, the data were log2 transformed and DWD normalized [30] to reduce 
biases that can result from differences in batch processing and platforms.
3.3.11   Statistical Analysis
To identify candidate fractions significantly more effective against BL-CL 
than Luminal/HER2+ breast cancer, preliminary statistical analysis was performed 
using the unpaired two-sample equal variance t-test built into the Microsoft Excel 
program. Final statistical assessment was performed for the fractions from the 
sponge PNG07-3-073 by re-analyzing statistical significance test based on the 
normality of the data. Gaussian distribution of the data was checked for using three 
different tests built into the GraphPad Prism 6 software:  the D’Agostino-Pearson 
omnibus test, the Shapiro-Wilk test and The Kolmogorov-Smirnov test (with the 
Dallal-Wilkinson-Lilliefor corrected P value). Dot plots were then created using 
Graphpad Prism 6.01 and a standard two-tailed Mann-Whitney U-test was used 
to test for statistical significance, with the exception of the dot plot diagrams for 
halistanol sulfate, dorsomorphin C, Ly2603618 and dorsomorphin C + Ly2603618 
where an unpaired t-test with was used due to the normality of the data. To compare 
the difference of protein expression between treated cell lines and their DMSO 




3.4.1  Identification of Topsentinol L Trisulfate as a  
Selective Inhibitor of BL-CL
The goal of this study is to find a novel inhibitor of BL-CL, describing the 
pathways effectively blocked by the compound, and projecting treatment efficacy 
across other cancer types. We aimed to achieve this through a stepwise approach 
by 1) screening MICL for fractions that exhibited tumoricidal properties, 2) selecting 
candidate fractions that displayed effectiveness against BL-CL, 3) separating the 
active compounds in the fractions, 4) identifying the active compound with anti-BL-
CL properties, 5) describing the cell signaling effects of the compound on BL-CL, 
6) projecting TLT sensitivity across human tumors of various cancer types using a 
gene-expression signature  (Figure 3.1A). 
To identify fractions with tumoricidal activity, we began by screening 2778 
fractions from MICL against a panel of 16 cell lines (Figure 3.1B “Screen 1”). These 
fractions represent complex mixtures, and served as a starting point to identify 
promising hits [11,12]. From this screen, we selected 107 HP20 fractions based 
on differential tumoricidal activity among the 16 cell lines, eliminating all fractions 
that were universally toxic or that showed minimal anticancer activity. We then 
added an additional 85 previously-unscreened HP20 fractions from MICL based 
on chemical similarity to the 107 selected fractions, directed by chemo-taxonomic 
judgment of source organism [11,12]. Next, we screened these 192 HP20 fractions 
against a panel of 35 breast cancer and 37 lung cell lines to identify fractions 
effective against breast cancer in general, and BL-CL in particular (Screen 2). 
We selected 34 HP20 fractions based on their selectivity against breast cancer 
compared to lung cancer, with only seven of those fractions displaying significant 
subtype selectivity against BL-CL (Figure 3.1B “Screen 2”). These seven fractions 
were then fractionated further into 20 subfractions each (labeled M1-M20) using 
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LCMS for the purposes of additional active compound separation, and screened 
in two doses against a panel of 33 breast cancer cell lines (Figure 3.1B “Screen 
3”). This screen identified five subfractions with significant selectivity against BL-
CL, out of which three subfractions originated from the marine sponge PNG07-3-
073 F2 fraction. We analyzed the results of all three screens retrospectively, and 
observed that the PNG07-3-073–F2 was initially identified as a candidate with 
increased tumoricidal activity against BL-CL (Figure 3.2A, Figure 3.1B). The HP20 
fractionation of the sponge also resulted in four other fractions, FW, F1, F3 and 
F4; however, none exhibited sufficient tumoricidal activity and therefore did not 
proceed past the first screen. The F2 was the only fraction from the Topsentia 
sponge PNG07-3-073 to exhibit anti-BL-CL activity (Figure 3.1B). This activity was 
maintained after further fractionation of F2 via LC/MS into 20 subfractions. The M6 
subfraction in particular displayed significant effectiveness against BL-CL (Figure 
3.2B, Figure 3.1B). 
Our next step was to proceed with the identification of the active compounds 
in the M6 subfraction with the aim of isolating the single compounds inducing this 
response (Figure 3.1A). For this purpose, a large amount of product was needed, 
and a scaled-up extraction of bulk PNG07-3-073 sponge ensued. This culminated 
in the purification of two isolates: isolate 1 and 2. 1D NMR analysis (Supplementary 
Table 3.3) identified isolate 1 as the previously reported metabolite halistanol 
sulfate [31] (Figure 3.2C, Supplementary Figure 3.2-3.3) and was validated 
using high-resolution electrospray ionization mass spectrometry (HRESIMS, low-
resolution spectrum shown in Supplementary Figure 3.4). Isolate 2 was identified 
via 1D (Supplementary Figure 3.5-3.6) and 2D (Supplementary Figure 3.7-3.11) 
NMR analysis (Supplementary Table 3.3) as a previously uncharacterized sulfated 
sterol similar to the known compound topsentinol L but with three sulfate groups 
[32] (Figure 3.2D). The structure of the compound was corroborated by the data 
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obtained through HRESIMS (Low-resolution spectrum shown in Supplementary 
Figure 3.12). We named this compound topsentinol L trisulfate, or TLT (Figure 
3.2D). Halistanol sulfate and TLT were then screened against a panel of 30 breast 
cancer cell lines, and tested for effectiveness against BL-CL. TLT showed significant 
tumoricidal activity against BL-CL breast cancer compared to other subtypes (p = 
0.0076, Figure 3.2C, Figure 3.1B). Halistanol sulfate did not exhibit such activity 
(p = 0.247, Supplementary Figure  3.13). Through a multistep screening and 
fractionation process, we identified a novel sulfated sterol, TLT, which exhibits 
significant subtype selectivity against BL-CL.
3.4.2  Topsentinol L Trisulfate Treatment Inhibits AMPKα  
and CHK1 but Activates p38
Our next goal was to analyze and describe the signaling effects that are 
induced by TLT in cancer cells. For this purpose, we treated eight TLT-sensitive 
BL-CL cell lines with TLT or DMSO control and screened for 217 phosphorylated 
and nonphosphorylated protein changes using reverse phase protein array (RPPA) 
[20]. From this screen, we identified 21 proteins that exhibited a 15% or more 
upregulation or downregulation in protein level, with only eight of these proteins 
exhibiting statistically significant changes (Supplementary Table 3.4). To focus our 
research and narrow down our investigation, we studied the deregulation of three 
proteins, AMPK, CHK1 and p38, for the reasons outlined. AMPK phosphorylation 
recorded the biggest statistically significant change compared to DMSO control of 
all proteins, with 35% reduction in Thr172 phosphorylation, which is required for 
AMPK activation [33] (p = 0.031, Figure 3.3C). Interestingly, phosphorylation of 
ACC, a direct downstream effector of AMPK [34], was also significantly inhibited, 
recording a 26.5% reduction in Ser79, supporting the observation of AMPK 
inhibition (Supplementary Table 3.3, p = 0.03). We also observed significant 
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changes in phosphorylation of CHK1, recording a 16% downregulation in the 
nuclear localization mark Ser345 [35] (p = 0.012, Figure 3.3C). CHK1 has recently 
been suggested to represent a therapeutic target in triple negative breast cancer 
(TNBC) [36], therefore making its inhibition following TLT treatment a potential 
cause of treatment effectiveness. Upregulation of p38 phosphorylation was the 
most significant change observed upon treatment with TLT, with 23% increase in 
Thr180-Tyr182 phosphorylation (p = 0.003, Figure 3.3C). The activation of p38 
has been shown to lead to the direct phosphorylation of BimEL and the induction 
of apoptosis [37].
In order to validate the observations of AMPK, p38, and CHK1 protein 
phosphorylation deregulation following TLT treatment in the RPPA screen, we 
analyzed phosphorylation levels by western blotting. The most consistent down-
regulation observed was an inhibition of AMPK activation across all four cell lines 
(Figure 3.3D). CHK1 activity measured by the phosphorylation of the activation 
site of the protein, Ser317, was inhibited by TLT [38] (Figure 3.3D). In addition, 
the phosphorylation of p38 was also upregulated in three out of four cell lines, 
confirming previous results (Figure 3.3C-3D). These data describe the landscape 
of proteomic changes induced following TLT treatment in BL-CL cells.
3.4.3  Inhibition of AMPK and CHK1, Alone or in Combination 
 is Effective Against BL-CL
Due to the consistent nature of the observation of AMPK inhibition (either 
the protein itself or its downstream effector ACC) and CHK1 (the inhibition of two 
separate activation marks Ser345 and Ser317), as well as the recent discovery of 
CHK1 treatment efficacy against TNBC [36], we decided to test the importance of 
the inhibiting AMPK and CHK1 in BL-CL. As such, we investigated the effects of 
AMPK, CHK1 and AMPK1+CHK1 small molecule targeted inhibition on a panel 
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of 20 breast cancer cell lines. We screened the panel with dorsomorphin C, an 
AMPK inhibitor [39], Ly2603618, a CHK1 inhibitor in phase two clinical trials [40], 
and the combination of both. Our results showed that either treatment strategy is 
significantly more effective against the BL-CL subtype than Luminal/HER2+ breast 
cancer (Figure 3.4). Dorsomorphin C was more than four times more effective 
against BL-CL (average EC50 = 9.33 µM) compared to Luminal/HER2+ breast 
cancer (average EC50 = 37.87 µM), which was a significant difference (p = 0.011, 
Figure 3.4A). Ly2603618 on the other hand was almost eight times more toxic 
against BL-CL (average EC50 = 0.72 µM) in comparison to Luminal/HER2 breast 
cancer (average EC50 = 5.73 µM), which was also a significant difference (p = 
0.001, Figure 3.4B). Interestingly, the combination therapy was also significantly 
more effective against BL-CL (p= 0.005) (Figure 3.4C). These results validate the 
importance of the inhibitory effects of TLT on AMPK and CHK1 in BL-CL, and 
suggest the potential use of AMPK or CHK1 inhibition as a treatment. 
3.4.4  TLT Sensitivity Signature Predicts Breast and Bladder  
Cancer Response in Human Tumors
Next, we sought to identify classes of solid tumors that are most sensitive 
to TLT using an unbiased computational approach. The gene-expression profiles 
of cancer cells are a valuable tool in the comprehension of transcriptional 
changes indicative of treatment. These profiles enable the identification of drug 
sensitivity across various cancer types. Such expression profiles may be used 
to characterize the genes whose expression is indicative of drug response [29]. 
Accordingly, we generated a TLT sensitivity signature that reflected the genomic 
changes in eight TLT-sensitive BL-CL cell lines (Figure 3.5A). We treated the cell 
lines with either TLT or DMSO control and used RNA-sequencing to profile the 
samples. We identified 131 genes that significantly upregulated or downregulated 
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and incorporated the expression values for these genes into a predictive signature 
(Figure 3.5A). We then used this signature to predict drug sensitivity for the tumors 
from the PANCAN12 gene-expression dataset, which contains expression profiles 
for 12 cancer types [22,41]. The outcome of this process is a probability for each 
tumor sample, indicating how likely each tumor would respond to TLT treatment. 
Breast (mean = 0.71) and bladder cancer (mean = 0.69) were predicted to be 
most sensitive to TLT (1.00 is highest possible sensitivity, and 0.00 is lowest), 
while glioblastoma was predicted to be least sensitive (mean = 0.16, Figure 3.5B). 
Low TLT sensitivity was also predicted for uterine corpus endometrial carcinoma 
(UCEC mean = 0.29) and kidney renal clear cell (KIRC mean = 0.35). Medium 
TLT sensitivity was recorded for the rest of the profiled cancer types, including 
colon adenocarcinoma (COAD mean = 0.42), lung adenocarcinoma (LUAD mean 
= 0.43) and ovarian serous cystadenocarcinoma (OV mean = 0.56) (Figure 3.5B). 
These results are in line with the in vitro observations of TLT effectiveness against 
breast cancer (BL-CL in particular) and suggest future investigation of TLT as an 
effective therapeutic lead against bladder cancer. 
3.5  Discussion
We have identified and described a previously uncharacterized trisulfated 
sterol that we have named topsentinol L trisulfate and which exhibits increased 
tumoricidal activity against BL-CL. Interestingly, halistanol sulfate, another 
trisulfated sterol isolated from the same marine organism as TLT, did not exhibit 
similar activity against BL-CL (Supplementary Figure 3.13). This could potentially 
be attributed to the differences in the side chains of these two compounds, which 
are otherwise structurally similar (Figure 3.2C-D). 
Furthermore, we describe the treatment effect of TLT on BL-CL, highlighting 
the particular changes in the activation of AMPK, CHK1 and p38. AMPK is a 
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heterotrimeric serine/threonine kinase complex that is regulated by adenylate 
levels in the cell and functions as part of an evolutionarily conserved energy-
sensing pathway [42,43]. The effective result of AMPK activation is the avoidance 
of bioenergetic catastrophe and cell death through the conservation of cellular 
energy [43]. Interestingly, the role of AMPK in cancer is complex, as AMPK can 
exert pro- or antitumor effects based on cell context. AMPK is central to a tumor 
suppressor network, the LKB1-AMPK-TSC-mTOR signaling cascade, known 
to regulate cell growth and proliferation in response to stress [44]. Conversely, 
retaining continuous activation of AMPK leading to an enhanced ability to adapt to 
metabolic stress may function to promote tumor survival and growth. For example, 
the activation of AMPK in response to stresses such as hypoxia and nutrient 
deprivation provides cancers cells with the metabolic flexibility needed for survival 
[43]. These dueling roles of AMPK highlight the complexity and dichotomy of the 
kinase’s role in cancer cells. AMPK agonists acting as anticancer agents have 
been suggested through the use of the therapeutic biguanides: metformin and 
phenformin. Metformin is currently used to treat type II diabetes and has been 
associated with a significantly lower cancer incidence in patients relative to those 
using other medications to manage their diabetes [39,45]. However, recent work 
has indicated that the antitumorigenic effects of metformin and another known 
AMPK agonist, AICAR, are due to AMPK-independent effects [46]. Interestingly, 
other studies have implicated AMPK as a mediator of cellular proliferation and 
survival, showing the promising effect of AMPK inhibition as a cancer therapy 
[47,48]. We observe similar effects against breast cancer, and particularly the BL-
CL subtype which exhibits higher sensitivity against dorsomorphin C than Luminal/
HER2+ breast cancer (Figure 3.4A). This observation is in line with the AMPK 
inhibitory effects induced in BL-CL breast cancer when treated with TLT (Figure 
3.3C-D). 
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Another aspect of the inhibitory effects promoted by TLT treatment was the 
downregulation of CHK1 activation.  Upon cellular exposure to various genotoxic 
stresses, CHK1 is activated by ATR-mediated phosphorylation following DNA-
damage leading to the phosphorylation of cdc25. CHK1 assumes the role of the 
major cell-cycle checkpoint kinase mediating S- and G2-arrest [36]. In BL-CL, the 
rationale of CHK1 targeted therapy is supported by the documented evidence of 
alterations in the DNA damage repair machinery through either the high rate of 
BRCA or p53 mutations [6,7,9]. Therefore, another loss of a DNA damage repair 
component may lead to the cell’s inability to properly fix chromosomal damage 
and enter apoptosis. Indeed, Albiges, et al. have shown that CHK1 is potential 
therapeutic target in TNBC, with CHK1 inhibition observed to induce mitotic cell 
death in TNBC cell lines [36]. In our work, we complement this finding by recording 
the selectivity of CHK1 inhibition against BL-CL, which is concordant with the 
TNBC subtype (Figure 3.4B). The inhibitory effects of TLT on AMPK and CHK1 
shed light on the potential therapeutic benefit of AMPK and/or CHK1 inhibition 
on BL-CL. However, further work is required to validate these findings. Although 
dorsomorphin C is a potent AMPK inhibitor, studies have shown this compound to 
exhibit high affinity towards other proteins such as BMP and ALK [49]. 
Finally, our work describes the projected efficacy of TLT against a variety of 
human tumors, highlighting the optimal effect of the compound against breast and 
bladder cancer. In a recent TCGA study characterizing the molecular landscape 
of urothelial bladder carcinoma, a p53 mutation rate of 49% was recorded in 
the samples tested [50], drawing a similarity to the common observation of p53 
mutation in BL-CL. More interestingly, among the key pathway nodes deregulated 
in bladder cancer, the LKB1/STK11-TSC-mTOR node was among the most 
commonly deregulated. LKB1, the deactivator of AMPK, was recorded to contain 
copy number alternations (CNAs) in 11% of all cases. TSC1 and TSC2 recorded 
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CNAs in 16% and 9% of all cases, as well as inactivating mutations in 8% and 2%, 
respectively [50]. Thus, one hypothesis is that the inhibitory effect of TLT on CHK1 
and AMPK (and subsequently the LKB1-AMPK-TSC-mTOR node) could lead to 
an equally effective response against bladder cancer. Further work is needed to 
elucidate the exact mechanism of action of TLT and its projected effectiveness 
against bladder cancer. 
In this study, we have described the discovery and identification of a 
previously unreported sulfated sterol, as well as its signaling effect on BL-CL. We 
have described two potential therapeutic targets of BL-CL that can be exploited 
for the benefit of treatment efficacy. This lays the groundwork necessary for the 
exploration of AMPK and CHK1 as potential targets of BL-CL treatment, with a 
need to further characterize and delineate TLT’s role as an investigational anti-BL-
CL compound. 
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Figure 3.1: The overall design of the step-wise drug screen. (A) 2778 HP20 
fractions were first screened. 
One hundred ninety-two HP20 fractions were selected based on tumoricidal 
properties and chemo-taxonomic judgment of source organism. These fractions 
were then screened to identify BL-CL selective inhibitors. Seven candidate 
fractions were identified and further subfractionated. The subfractions were in 
turn screened for anti-BL-CL properties. After a candidate anti-BL-CL subfraction 
was identified, the active compound of the fraction was isolated, and its effect on 
BL-CL analyzed through proteomic and biochemical methods. A gene-expression 
signature of sensitivity to the active compound was then generated and used to 
project compound sensitivity across various cancer types. (B) The path towards 
identifying TLT. Marine sponge PNG07-3-073 was diced and soaked in methanol 
to obtain a crude extract, which was fractionated on HP20SS resin. Among the 
five fractions obtained, only the F2 fraction exhibited tumoricidal activity (Screen 
1). This activity was amplified against BL-CL (screen 2). PNG07-3-073-F2 was 
then further fractionated, and the subfractions investigated for anti-BL-CL activity, 
where the M6 fraction was identified as being BL-CL selective (Screen 3). Large-
scale isolation of PNG07-3-073 ensued, culminating in the purification of TLT and 
its identification as the active compound in PNG07-3-073 responsible for anti-BL-
CL effects (Screen 4).
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Figure 3.2: Topsentinol L trisulfate, isolated from the marine sponge Topsentia sp. 
(PNG07-3-073), is selective against BL-CL. 
Cell lines were divided accordingly and scatter dot diagrams plotted. Every 
dot represents a cell line, with the y value representing the cell line’s viability 
or compound EC50 posttreatment. The horizontal line indicates the mean for 
every group. BL-CL cell lines exhibit significantly lower cell viability when treated 
with (A) PNG07-3-073-F2 and (B) PNG07-3-073-F2-M6 than Luminal/HER2+ 
cell lines. (C) Chemical structure of halistanol sulfate. (D) Chemical structure 
of topsentinol L trisulfate. (E) Response to topsentinol L trisulfate treatment as 
measured by compound EC50. BL-CL cell lines are significantly more sensitive to 
TLT than Luminal/HER2+ cell lines. 
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Figure 3.3: TLT inhibits AMPK and CHK1 but activates p38. 
(A) A panel of eight BL-CL cell lines were treated with TLT at a 105µM dose 
(approximate average EC75 dose across all eight lines) for 6 hrs, and compared 
to DMSO control via RPPA that investigated 217 proteins. Eight proteins 
displayed 15% or more significant deregulation in protein levels, among which, 
AMPK, CHK1 and p38 are displayed here in bar graphs. Error bars represent 
SEM. (B) Observations made for p38, AMPK and CHK1 in the RPPA experiment 
were validated by western blotting. A panel of four BL-CL cell lines were treated 
similarly with TLT at a 105µM dose for 6 hrs, and compared to DMSO control. 
TLT treatment inhibits AMPK and CHK1, and activates p38.  
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Figure 3.4: Singular or dual inhibition of AMPK and CHK1 is selective against BL-
CL. 
(A) Cell lines were divided accordingly and scatter dot diagrams of treatment 
EC50 values plotted. Every dot represents a cell line, with the y value 
representing the cell line’s treatment EC50 and the horizontal line indicating 
the mean for each group. BL-CL cell lines are significantly more sensitive to (A) 
AMPK inhibition through dorsomorphin C, (B) CHK1 inhibition through Ly2603618 
and (C) the combined inhibition of both AMPK and CHK1 through concurrent 
treatment of dorsomorphin C and Ly2603618.
Figure 4 
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Figure 3.5: TLT sensitivity is predicted in breast and bladder cancer using gene-
expression signature analysis. 
(A) The gene-expression signature for TLT sensitivity was generated by treating 
eight BL-CL cell lines with either TLT or DMSO. The heatmap columns are the 
eight cell lines making up eight controls on the left (treated with DMSO) and eight 
treated samples on the right (treated with TLT). Each row represents a gene that 
is part of the signature. There are a total of 131 genes making up the signature. 
Red indicates upregulation while blue indicates downregulation of the gene. (B) 
The TLT sensitivity signature was used to project the sensitivity of 12 different 
cancers. Results are shown in a bar graph where the x axis represents the 12 
cancer types assayed and the y axis represents the predicted score of TLT 
sensitivity (minimum = 0, maximum = 1). Each column portrays the mean of the 
TLT sensitivity scores across the samples in a particular cancer type. The error 
bars indicate SEM. Breast and bladder cancer were predicted to be the most 
sensitive to TLT treatment, with glioblastoma being the least sensitive. Legend = 
BLCA: bladder urothelial carcinoma. BRCA: breast invasive carcinoma. COAD: 
colon adenocarcinoma. GBM: glioblastoma multiforme. HNSC: head and neck 
squamous cell carcinoma. KIRC: kidney renal clear cell carcinoma. LUAD: lung 
adenocarcinoma. LUSC: lung squamous cell carcinoma. OV: ovarian serous 





































































Supplementary Figure 3.1: Image of the marine invertebrate Topsentia sp. 
sponge labeled PNG07-3-073. 
The sponge specimen PNG07-3-073 was identified as Topsentia sp. (OTU 
UU1273), order Halichondrida, family Halichondriidae. The creamy white sponge 
is massive with thick fistular processes, a firm texture and slightly hispid surface. 
The ectosome is not detachable, consisting of a thin paratangential layer of 
spicules with protruding choanosomal spicules. The interior of the sponge is 
densely spiculous and completely disorganized with plumose bundles of spicules 
just below the surface, spongin not visibly present. The spicules are fusiform 
oxea in a range of sizes and widths, generally in categories: ~1125-1325 × 
42-48µm, 715-1050 × 25µm, 525-825 × 15µm. Topsentia sp. (OTU UU1273) 
does not compare entirely to previously described species of Topsentia and 
likely represents an undescribed species. The sponge was collected by SCUBA 
November 21, 2007 from New Britain, Papua New Guinea (S 05° 19.680’, 
E 150° 17.674’) and immediately frozen. The specimen has been described 
in SpongeMaps, available at the following link: http://www.spongemaps.
org/#!Topsentia-sp-OTU-UU1273-demosponge/zoom/c21kz/imagel3v
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Supplementary Figure 3.4: Low-resolution mass spectra for (A) halistanol sulfate.
A
HRESIMS: m/z = 607.2958
[M-SO3-H]–, calculated for
C29H51O9S2, 607.2980,
Δ = -3.9 ppm
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Supplementary Figure 3.13: Halistanol sulfate is not selective against BL-CL in 
comparison to Luminal/HER2+ breast cancer. 
The cell lines of the investigated breast cancer panel were divided accordingly 
and scatter dot plot diagrams of halistanol sulfate EC50 values plotted. Every 
dot represents a cell line, with the y value representing the cell line’s halistanol 
sulfate compound EC50 and the horizontal line indicating the mean value for 
every group. There is no significant difference between the response of BL-CL 
and Luminal/HER2+ cell lines to halistanol sulfate.
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Characteristics of the breast cancer cell lines used in the study for all screens 
and drug response assays. 
 
 
Breast Cancer Cell Line ER PR HER2 Gene-expression Subtype Media Screen 1 Screen 2 Screen 3 Screen 4 AMPKi/CHKi Screen
AU565 - - + luminal/HER2 positive RPMI x x x x
BT20 - - - basal DMEM x x x
BT474 + + + luminal/HER2 positive DMEM x x x x x
BT483 + + - luminal RPMI x x x x
BT549 - - - claudin low RPMI x x x
Cama-1 + - - luminal DMEM x x x
HCC1143 - - - basal RPMI x x x x
HCC1395 - - - Basal RPMI x x x
HCC1419 - - + luminal/HER2 positive RPMI x x x x
HCC1500 + + - Basal RPMI x
HCC1569 - - + basal/HER2 positive RPMI x x x
HCC1599 - - - basal RPMI x x
HCC1806 - - - basal RPMI x x x x
HCC1937 - - - basal RPMI x x x x
HCC1954 - - + basal/HER2 positive RPMI x x x
HCC2218 - - + luminal RPMI x x x
HCC38 - - - claudin low RPMI x x x x
HCC70 - - - basal RPMI x x x x
Hs578T - - - claudin low DMEM x x x x x
JIMT-1 - - + basal/HER2 positive DMEM x x x
MCF7 + + - luminal DMEM x x x x x
MD134VI + - - luminal RPMI x x x
MD157 - - - claudin low DMEM x x x x
MD175VII + - - luminal RPMI x x x x
MD231 - - - claudin low RPMI x x x x x
MD415 + - - luminal RPMI x x x x
MD436 - - - claudin low RPMI x x x x
MD453 - - - luminal RPMI x x x
MD468 - - - basal RPMI x x x x
MDAMB361 + - + luminal/HER2 positive DMEM x x x
SKBR3 - - + luminal/HER2 positive RPMI x x x x
T47D + + - luminal RPMI x x x x
UACC812  - - + luminal/HER2 positive DMEM x x x x
ZR75-1 + - - luminal RPMI x x x x
ZR75-30 + - + luminal/HER2 positive RPMI x
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Supplementary Table 3.2
Characteristics of the lung cancer cell lines used in the study for all screens and 
drug response assays. 
 
 
Lung Cancer Cell Line Subtype K-Ras Mut P53 Mut EGFR Mut Media Screen 1 Screen 2
A549 Adenocarcinoma G12S x x F12K x
CALU3 Adenocarcinoma x M237I x EMEM x
H1155 Large cell Q61H R273H x ACL-4 x
H1355 Adenocarcinoma G13C E285K Q1159H ACL-4 x
H1373 Adenocarcinoma G12C E339* Intron RPMI x
H1395 Adenocarcinoma x x x RPMI x
H1437 Adenocarcinoma x R267P x RPMI x
H1563 Adenocarcinoma x x x RPMI x x
H1581 Large cell x Q144* x ACL-4 x x
H1650 Adenocarcinoma x V225_splic ELREA746del RPMI x x
H1651 Adenocarcinoma x C176Y x ACL-4 x
H1693 Adenocarcinoma x Q331_splic x RPMI x
H1703 Adenocarcinoma x A307_splic x RPMI x
H1792 Adenocarcinoma G12C E224_splicex RPMI x
H1793 Adenocarcinoma x R209* C311F HITES x
H1944 Adenocarcinoma G13D x x RPMI x x
H1975 Adenocarcinoma x x T790M, L858R RPMI x x
H2009 Adenocarcinoma G12A R273L Intron HITES x
H2030 Adenocarcinoma G12C G262V x RPMI x
H2085 Adenocarcinoma x ND ND ACL-4 x
H2122 Adenocarcinoma G12C C176F, Q16x RPMI x
H2126 Adenocarcinoma x E62* x ACL-4 x
H23 Adenocarcinoma G12C M246I x RPMI x x
H2405 Adenocarcinoma x x x ACL-4 x
H322 Adenocarcinoma x R248L x RPMI x
H358 Adenocarcinoma G12C x x RPMI x
H441 Adenocarcinoma G12V R158L x RPMI x
H460 Large cell Q61H x x RPMI x
H520 Squamous x W146* x RPMI x x
H522 Adenocarcinoma x P191fs FRA   x RPMI x
H661 Large cell x R158L, S21 x RPMI x x
H838 Adenocarcinoma x x x RPMI x
HCC4006 Adenocarcinoma x x ELR746del INFRAME RPMI x x
SKLU1 Adenocarcinoma G12D H193R x EMEM x
SKMES1 Squamous x E298* x EMEM x
SW1573 Squamous G12C Intron x RPMI x
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Supplementary Table 3.3




 Halistanol sulfate (mkh2-141-2) Topsentinol L trisulfate (mkh2-141-4) 
Position C (mult.) H (mult., J in Hz) C (mult.) H (mult., J in Hz) 
1 39.4 2.07 (br d, 14.3) 39.4 2.07 (m) 
  1.48 (dd, 15.4, 2.9)  1.48 (dd, 14.9, 3.7) 
2 75.7 4.80 (s) 75.7 4.80 (s) 
3 75.6 4.75 (s) 75.6 4.75 (br d, 22.3) 
4 25.2 2.28 (br d, 14.6) 25.2 2.28 (br d, 14.5) 
  1.79 (br t, 13.4)  1.78 (m) 
5 45.5 1.63 (m) 45.5 1.62 (m) 
6 78.9 4.19 (td, 11.1, 4.4) 78.9 4.19 (td, 11.1, 4.4) 
7 40.2 2.37 (dt, 12.2, 4.3) 40.2 2.36 (dt, 12.1, 4.3) 
  1.05 (m)  1.04 (m) 
8 35.3 1.53 (m) 35.3 1.53 (m) 
9 56.0 0.76 (m) 56.0 0.75 (m) 
10 37.8  37.8  
11 22.0 1.54 (m) 22.0 1.55 (m) 
  1.31 (m)  1.31 (m) 
12 41.3 2.00 (br d, 12.4) 41.2 2.00 (dt, 12.4, 2.9) 
  1.15 (m)  1.17 (m) 
13 43.9  43.8  
14 57.8 1.11 (m) 57.8 1.11 (m) 
15 25.3 1.63 (m) 25.3 1.59 (m) 
  1.11 (m)  1.11 (m) 
16 29.3 1.86 (m) 30.3 1.73 (m) 
  1.29 (m)  1.29 (m) 
17 57.5 1.16 (m) 57.5 1.19 (m) 
18 15.4 1.05 (s) 15.4 1.05 (s) 
19 12.6 0.69 (s) 12.8 0.71 (s) 
20 37.8 1.38 (m) 42.2 2.06 (m) 
21 19.7 0.94 (d) 21.9 1.05 (d, 7.2) 
22 36.8 1.56 (m) 140.8 5.14 (dd, 15.2, 8.5) 
  0.90 (m)  NA 
23 29.4 1.63 (m) 128.5 5.05 (dd, 15.6, 9.5) 
  0.71 (m)  NA 
24 45.5 0.99 (m) 57.8 1.34 (m) 
25 34.2  29.9 a 1.70 (m) a 
26 27.9 0.86 (s) 22.3 a 0.86 (dd, 6.6, 1.6) a 
27 27.9 0.86 (s) 19.8 a 0.80 (dd, 6.7, 4.7) a 
28 15.1 0.83 (d) 29.9 b 1.70 (m) b 
29 27.9 0.86 (s) 22.2 b 0.86 (dd, 6.6, 1.6) b 
30 NA NA 19.6 b 0.80 (dd, 6.7, 4.7) b 
 
a Chemical shifts cannot be distinguished from those denoted by b. 
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Supplementary Table 3.4
RPPA results of the eight BL-CL cell lines treated with DMSO or TLT. 
 
 
Protein Paired TTEST DMSO Av TLT Av Mean diff DMSO-M4 % Change
AMPK-alpha_pT172 0.030926158 0.2468539 0.18237 0.06448569 -35.360163
14-3-3-epsilon 0.127055041 0.0924194 0.08764 0.004775493 -5.448744719
14-3-3-zeta 0.611359948 0.6997833 0.69274 0.007044538 -1.016911279
4E-BP1 0.88102686 0.2872652 0.286 0.001265921 -0.442630957
4E-BP1_pS65 0.688000793 0.6132918 0.60668 0.006608546 -1.089290952
4E-BP1_pT37_T46 0.052849589 0.7249001 0.83875 -0.11385355 13.57413446
53BP1 0.129295665 0.4471605 0.50738 -0.060216947 11.86827429
A-Raf 0.021802658 0.3242939 0.30103 0.023259764 -7.726620108
MAPK_pT202_Y204 0.063897497 0.3657461 0.27199 0.09375541 -34.47007848
ACC1 0.057831968 0.7090081 0.66169 0.047320333 -7.151459425
ACVRL1 0.204285214 0.0932188 0.09812 -0.004902111 4.995992268
ADAR1 0.722298854 0.1220255 0.12328 -0.001252066 1.015647984
Akt 0.019548209 0.572984 0.52345 0.04953045 -9.462243974
Akt_pS473 0.956418547 0.3849057 0.38686 -0.001955655 0.505518217
Akt_pT308 0.848831423 1.0898163 1.07076 0.019051852 -1.779275781
AMPK-alpha 0.494529968 0.8115008 0.82971 -0.01821201 2.194977551
FAK_pY397 0.080659613 0.0997996 0.08071 0.019094485 -23.65957935
ACC_pS79 0.023981823 0.6414503 0.51904 0.122410764 -23.5840916
Annexin-VII 0.479745507 0.1808896 0.19652 -0.015631946 7.954316733
AR 0.086105524 0.1613788 0.15309 0.008291424 -5.416139865
ARHI 0.374227021 0.0561487 0.0545 0.001644846 -3.017852599
ATM 0.310104666 0.1761461 0.17153 0.004614255 -2.690027967
ATM_pS1981 0.937022455 0.0777696 0.07816 -0.000390239 0.499282649
ATP5H 0.186610373 0.0743909 0.07776 -0.003372651 4.337059112
ATR 0.92837797 0.2607643 0.26007 0.000696483 -0.26780838
b-Catenin 0.584632507 0.6792402 0.71601 -0.036766439 5.134930087
b-Catenin_pT41_S45 0.070481607 0.1303322 0.13996 -0.009625835 6.877656406
B-Raf 0.032395628 1.009608 0.94963 0.059981572 -6.316333569
B-Raf_pS445 0.778696211 0.1716865 0.17297 -0.001285076 0.742940326
Bad_pS112 0.010420165 0.4945067 0.55515 -0.060640319 10.9232895
Bak 0.008721632 0.1909752 0.2054 -0.0144239 7.022377178
BAP1 0.259977565 0.2223549 0.21511 0.007244081 -3.367604315
Bax 0.343854359 0.3507281 0.36731 -0.016583733 4.514891461
Bcl-xL 0.13933645 0.5464368 0.57938 -0.032944392 5.68613386
Bcl2 0.422689711 0.0737728 0.07546 -0.001686947 2.235559768
Beclin 0.302512426 0.1887283 0.22117 -0.032440994 14.66794427
Bid 0.654051893 0.2214305 0.22455 -0.003117031 1.388138801
Bim 0.601368016 0.5163407 0.53035 -0.014011711 2.641962346
BRCA2 0.634796435 0.1778776 0.18588 -0.008002506 4.305198123
GAPDH 0.076587901 0.511228 0.41902 0.092207104 -22.00536928
c-Kit 0.137841447 0.1486842 0.15822 -0.009531557 6.024403154
c-Met 0.100343269 0.149599 0.14234 0.007259813 -5.100362748
c-Met_pY1234_Y1235 0.607157419 0.1791378 0.1818 -0.002660777 1.463584969
c-Myc 0.823539509 0.3123089 0.3083 0.00400808 -1.300054814
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C-Raf 0.00569841 0.2922268 0.26106 0.031170474 -11.94013341
C-Raf_pS338 0.181233222 0.4905809 0.45703 0.033551782 -7.341279215
Caspase-7-cleaved 0.199719195 0.0678278 0.07255 -0.004718936 6.504683391
Caspase-8 0.111844814 0.3088891 0.29177 0.017117839 -5.866869961
Caveolin-1 0.330102248 0.454963 0.44035 0.014615083 -3.31898519
CD29 0.347436034 0.031597 0.03009 0.001504719 -5.00034688
CD31 0.027495297 0.0240145 0.02141 0.002608377 -12.18521243
CD49b 0.000681184 0.090206 0.08321 0.006999799 -8.412591597
CDK1 0.527951409 0.2966172 0.30303 -0.006412135 2.116011117
Chk1 0.517023385 0.4436631 0.43806 0.005598172 -1.277931995
Stat3_pY705 0.061361639 0.288247 0.23968 0.048567263 -20.26340212
Chk2 0.900777361 0.3054057 0.30321 0.002196345 -0.724366013
Chk2_pT68 0.234845145 0.1516815 0.15712 -0.005434188 3.458717341
Claudin-7 0.838258667 0.5496062 0.53524 0.014368512 -2.684510622
Collagen-VI 0.581827632 0.1085949 0.09859 0.010000297 -10.14284249
Complex-II-Subunit 0.019357592 0.4883395 0.5321 -0.043759206 8.223889209
Cox-IV 0.21180139 0.0470478 0.04401 0.003040435 -6.908917587
p70-S6K_pT389 0.031044202 0.1669332 0.14084 0.026097196 -18.53020434
Cyclin-B1 0.047649153 1.5024802 1.70111 -0.19862495 11.67622972
Cyclin-D1 0.255149632 0.3947857 0.37585 0.018939256 -5.039094233
Cyclin-E1 0.471229306 0.3046325 0.2948 0.009828166 -3.333793248
Cyclophilin-F 0.588089846 1.2412809 1.12366 0.117620772 -10.4676463
DJ1 0.057596359 0.3065183 0.31909 -0.012574353 3.940658557
Dvl3 0.305796393 0.3631395 0.35437 0.008770662 -2.475009209
E-Cadherin 0.414543231 0.2309039 0.26116 -0.030252555 11.58407426
E2F1 0.465992121 0.0490497 0.05045 -0.001399862 2.774776277
eEF2 0.024329272 0.4482607 0.42437 0.023888806 -5.629214761
eEF2K 0.019692069 0.5732332 0.5177 0.055530627 -10.72635653
EGFR 0.694306782 0.6800515 0.66891 0.011142733 -1.665807521
Smac 0.20574698 0.4343177 0.36964 0.064677673 -17.4974742
EGFR_pY1173 0.30499704 0.1638452 0.17395 -0.010102281 5.80766297
eIF4E 0.125804471 0.8195001 0.79346 0.026037641 -3.28152156
eIF4G 0.878724419 1.035565 1.03183 0.003731644 -0.361651783
ER-alpha 0.504178772 0.0388962 0.0377 0.001192711 -3.163397879
ER-alpha_pS118 0.634911633 0.3953871 0.39946 -0.004070958 1.019120408
ERCC1 0.007891293 0.1646311 0.19196 -0.02732517 14.23510243
Ets-1 0.436109849 0.2073012 0.20972 -0.002419888 1.153860178
FAK 0.00596371 0.3746999 0.35153 0.023166155 -6.590023246
Chk1_pS345 0.012431443 0.2876721 0.24789 0.039780631 -16.0476008
FASN 0.010279931 0.7383777 0.68099 0.057383377 -8.426410979
Fibronectin 0.287511878 0.0348751 0.03279 0.002080442 -6.34384711
FoxM1 0.021099513 0.466201 0.42671 0.039490719 -9.254691723
FoxO3a 0.551797236 0.1353121 0.1374 -0.002085824 1.518089719
FoxO3a_pS318_S321 0.943894769 0.5589604 0.56027 -0.001312249 0.234216082
G6PD 0.228099421 0.0796185 0.07617 0.003448534 -4.52742041
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Gab2 0.129420955 0.2553089 0.24282 0.012488801 -5.143232028
EGFR_pY1068 0.28897535 0.0780788 0.09203 -0.013946575 15.15514849
GATA3 0.444543139 0.2890905 0.27977 0.009317527 -3.330389022
GCN5L2 0.581933997 0.4024414 0.41069 -0.008251661 2.009204067
GPBB 0.693848285 0.2242394 0.23134 -0.00710235 3.070067796
GSK-3ab 0.107780308 0.8094326 0.82645 -0.017016942 2.059041866
GSK-3ab_pS21_S9 0.550735827 0.6241206 0.64794 -0.023816819 3.675790205
GSK-3b_pS9 0.177310106 0.4761323 0.5083 -0.03216499 6.327988207
Gys 0.995834943 0.518761 0.51881 -5.10903E-05 0.009847553
Gys_pS641 0.541992189 0.3732588 0.36622 0.007043452 -1.923308627
HER2 0.263192338 0.0281805 0.02605 0.002128034 -8.16827614
NDRG1_pT346 0.168014205 0.3168807 0.37585 -0.05897111 15.68998963
HER3 0.192076665 0.2256087 0.20685 0.018756371 -9.06751822
HER3_pY1289 0.334961404 0.3471657 0.33777 0.009395071 -2.781494189
Heregulin 0.356306262 0.158463 0.16414 -0.005672826 3.456177062
HIAP 0.418473854 0.4569881 0.44928 0.00770568 -1.715108173
Histone-H3 0.859920263 0.1358833 0.13816 -0.002276057 1.647415041
IGF1R-beta 0.633604069 0.2032754 0.20619 -0.002917845 1.415102345
HER2_pY1248 0.104377998 0.0403153 0.04791 -0.0075911 15.8456832
INPP4b 0.224786181 0.1661943 0.16219 0.004006157 -2.470067174
IRS1 0.149211343 0.6053276 0.58946 0.015868518 -2.692047293
JAB1 0.551441944 0.0690752 0.06787 0.001201038 -1.769508052
JNK_pT183_Y185 0.622517253 0.1801214 0.18676 -0.006641022 3.555867298
JNK2 0.620583516 0.4413883 0.43619 0.005199641 -1.192062542
Lck 0.404041823 0.1615087 0.15269 0.008820444 -5.776766198
Annexin-I 0.202592026 0.2944506 0.35136 -0.056913782 16.19793713
Mcl-1 0.869330062 0.3021391 0.30475 -0.002608929 0.856093758
MDM2_pS166 0.184798884 0.4228332 0.43978 -0.016949566 3.854077221
MEK1 0.749093243 0.4931058 0.48759 0.005517333 -1.131555193
MEK1_pS217_S221 0.330871457 0.4264982 0.40648 0.020019075 -4.924994372
MEK2 0.046725637 0.262228 0.24935 0.012881695 -5.166185233
Merlin 0.110425164 0.6224777 0.57406 0.048420054 -8.434701674
MIG6 0.65818707 0.2714421 0.26646 0.004981295 -1.869428612
MSH2 0.232864132 0.7096262 0.69032 0.019305584 -2.796611216
MSH6 0.353124034 0.8008488 0.8208 -0.019953461 2.43097042
mTOR 0.10247673 1.0000496 0.97459 0.025457724 -2.612141883
mTOR_pS2448 0.535634771 0.5736505 0.58052 -0.006872585 1.183860668
Myosin-11 0.130662479 0.2516351 0.24104 0.010593952 -4.3950794
Myosin-IIa_pS1943 0.136330833 0.5590272 0.52052 0.038505586 -7.397499919
N-Cadherin 0.115979527 0.108239 0.0995 0.008736554 -8.780236006
N-Ras 0.424040717 0.0373128 0.03559 0.001720188 -4.83299624
NAPSIN-A 0.000244622 0.1888714 0.1789 0.009967334 -5.571328945
c-Jun_pS73 0.039255625 0.2882244 0.34707 -0.058847805 16.95549391
NF-kB-p65_pS536 0.700093069 0.5674735 0.54107 0.026404604 -4.880082075
Notch1 0.661226615 0.6396916 0.65434 -0.01464397 2.237990814
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p16INK4a 0.089057378 0.2589195 0.24097 0.017949144 -7.448692453
p21 0.072152138 0.589791 0.68726 -0.09746523 14.18179013
p27-Kip-1 0.101448071 0.1353413 0.12438 0.010959469 -8.811151583
p27_pT157 0.628732156 0.4132618 0.42135 -0.008085064 1.918861914
p27_pT198 0.015523921 0.380493 0.4207 -0.040209916 9.557793229
p38-alpha 0.00774209 0.3541716 0.32024 0.033932183 -10.59587949
p38 0.03267437 0.8570567 0.8278 0.029257917 -3.534423672
p38_pT180_Y182 0.002755169 0.4029123 0.52386 -0.120951629 23.08836548
p53 0.314234566 0.0975719 0.09485 0.002724253 -2.872240696
Snail 0.021853524 0.2435867 0.32022 -0.076637945 23.93255874
p70-S6K1 0.172006967 0.2027094 0.1965 0.006210831 -3.160751165
PAI-1 0.360871698 0.7728393 0.79675 -0.02391276 3.001280111
PARP-cleaved 0.118830095 0.0705842 0.06733 0.00325635 -4.836555963
PARP1 0.967407249 2.6880892 2.69449 -0.006399885 0.237517567
Paxillin 0.906536745 0.5151816 0.51694 -0.001762799 0.341003507
PCNA 0.06253059 0.2458135 0.23039 0.015419488 -6.692659587
Pdcd-1L1 0.112960284 0.1537748 0.21549 -0.061714605 28.63927851
Pdcd4 0.2306148 0.4398906 0.47403 -0.034134929 7.201073805
PDGFR-beta 0.638238272 0.7599954 0.79413 -0.034136002 4.298533004
PDK1 0.004328426 0.1989206 0.17397 0.024949699 -14.34130609
PDK1_pS241 0.010023724 0.4803055 0.44315 0.037151425 -8.38341026
PEA-15 0.575925151 0.4603699 0.4734 -0.013030284 2.752488295
PEA-15_pS116 0.07112505 0.4775941 0.51308 -0.035485327 6.91614747
PI3K-p110-alpha 0.045315699 0.3424673 0.32277 0.019699858 -6.103421879
PI3K-p85 0.209222646 0.2749676 0.27946 -0.004493387 1.607876193
PKC-alpha 0.896269303 0.7304674 0.7277 0.002768541 -0.380451526
PKC-alpha_pS657 0.795719345 0.4284552 0.43106 -0.002602363 0.603716011
PKC-beta-II_pS660 0.425784911 0.7686049 0.80879 -0.040182907 4.968287878
PKC-delta_pS664 0.045976568 0.3448394 0.36918 -0.024340036 6.593008843
PMS2 0.025956644 0.801951 0.74703 0.054920915 -7.351901528
Porin 0.243883965 0.0857229 0.08904 -0.003322 3.730702144
PR 0.663238212 0.1169763 0.11619 0.000789801 -0.679769967
PRAS40_pT246 0.365275156 0.8290985 0.86475 -0.035650351 4.122624665
PREX1 0.101304994 0.1049792 0.09812 0.006861336 -6.992955773
PTEN 0.782392774 0.1851321 0.18314 0.001988066 -1.085520762
Rab11 0.858096277 0.0879305 0.08734 0.000591986 -0.677806514
Rab25 0.332786784 0.1389058 0.13712 0.001783779 -1.300869619
Rad50 0.960424116 0.4113952 0.41097 0.000428285 -0.104213934
Rad51 0.024369829 0.1550382 0.13781 0.017233102 -12.50541433
Raptor 0.79377184 0.762859 0.75543 0.007433942 -0.984074094
Rb 0.533730146 0.2241153 0.2198 0.004313551 -1.962473631
Rb_pS807_S811 0.457540895 1.1841248 1.11809 0.066029881 -5.90557026
RBM15 0.957138438 0.4360402 0.43545 0.000592611 -0.13609247
Rictor 0.689051732 0.6479663 0.6408 0.007167023 -1.11845059
Rictor_pT1135 0.017269911 0.6853876 0.62371 0.061679537 -9.889167527
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RSK 0.147394136 0.4682432 0.45481 0.013431948 -2.953301246
S6_pS235_S236 0.09647995 1.2531184 1.40306 -0.149946424 10.68706343
S6_pS240_S244 0.118730496 0.8496313 0.94022 -0.090591207 9.635081836
SCD 0.759737499 0.0673423 0.06663 0.000707615 -1.061931555
SETD2 0.041455038 0.1748269 0.16728 0.007542015 -4.508486479
SF2 0.082190928 0.0562108 0.05337 0.002836706 -5.314761793
Shc_pY317 0.413441153 0.3421638 0.33226 0.009902927 -2.980467043
TAZ 0.293525898 0.4116032 0.58673 -0.175121832 29.8473411
Smad1 0.109784621 0.2190075 0.20699 0.012015241 -5.804681259
Smad3 0.042150885 0.5352521 0.5145 0.020756397 -4.034318757
Smad4 0.109781972 0.1975331 0.18686 0.01066866 -5.709304748
14-3-3-beta 0.297467434 0.1205898 0.17484 -0.054254273 31.03008862
Src 0.921787018 0.2637837 0.26281 0.000976124 -0.371421462
Src_pY416 0.208694232 0.1672131 0.15217 0.015041977 -9.884909758
Src_pY527 0.10778136 0.700054 0.642 0.05805016 -9.042026273
IGFBP2 0.004643877 0.1284908 0.19396 -0.065470005 33.7542394
Stat5a 0.004748425 0.5811547 0.52104 0.060117804 -11.53810864
Stathmin-1 0.452980835 0.1374042 0.14212 -0.004714313 3.317171496
Syk 0.804047646 0.2295709 0.22859 0.000979491 -0.428489726
Cox2 0.267016058 0.1049197 0.17838 -0.073460635 41.18203035
TFRC 0.45006093 0.5982809 0.62051 -0.022225227 3.581790061
TIGAR 0.203513955 0.4447832 0.43667 0.008111844 -1.857654354
Transglutaminase 0.347628428 0.3099899 0.31823 -0.008237679 2.588612494
TSC1 0.724792685 0.6995556 0.70621 -0.006652592 0.942015755
TTF1 0.072765875 0.4216622 0.40529 0.016367572 -4.038438288
Tuberin 0.007348867 1.2912628 1.17141 0.119849468 -10.23118546
Tuberin_pT1462 0.472275507 0.3208728 0.30659 0.014281069 -4.658009245
TWIST 0.026724298 0.0787599 0.07013 0.00863235 -12.30950185
Tyro3 0.148506776 0.2903453 0.26374 0.026606514 -10.08820479
UBAC1 0.084205337 0.4482809 0.42428 0.023999931 -5.656613047
UGT1A 0.129590932 0.0798728 0.07732 0.002550457 -3.298473152
UQCRC2 0.968988613 0.097701 0.09758 0.000124445 -0.127535891
VEGFR-2 0.399973553 0.4634747 0.45786 0.005619443 -1.227340541
XRCC1 0.599402963 0.4539372 0.45771 -0.003775075 0.824770285
YAP 0.389819715 0.3792817 0.38599 -0.006706443 1.737473896
YAP_pS127 0.786380304 0.7320844 0.73928 -0.007192785 0.972948256
YB1 0.055196453 0.6676773 0.7363 -0.068626495 9.320405293
YB1_pS102 0.019015082 0.6649866 0.78032 -0.11532871 14.77975748
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4.1  Summary of Findings
This dissertation work identifies two novel therapeutic strategies personalized 
against two different complex cancer phenotypes using genomic classification 
and high-throughput drug screening. In Chapter 2, we showed the importance of 
incorporating global assessment of RAS pathway activity as means to classify the 
RAS-active NSCLC subtype. This allowed the grouping of NSCLC according to 
global activation status of the RAS pathway (independent of histological subtyping 
and RAS mutation) and permitting the identification of EGFR and MEK co-inhibition 
as a personalized treatment against this molecular subpopulation. Furthermore, this 
study provided strong evidence on the limitations of tailoring targeted therapeutics 
to tumors expressing particular mutations, as KRAS mutation status, 1) failed to 
predict EGFR+MEK co-inhibition treatment response, 2) did not account for RAS-
active NSCLC without a KRAS mutation, 3) left out a large population of NSCLC 
tumor cells with wild-type KRAS sensitive to the treatment. Through the use of 
a RAS gene-expression signature as a predictor of RAS pathway activation, we 
were able to classify NSCLC cells based on their RAS pathway activity profile. 
This allowed the identification of a therapy particularly effective against NSCLC 
cells with an active RAS pathway, independent of KRAS mutation status. Indeed, 
the signature succeeded as a biomarker of response to co-inhibition of EGFR and 
MEK where KRAS mutation status failed.
In Chapter 3, we addressed the need for therapeutic options in the BL-
CL complex cancer phenotype by identifying a novel natural product personalized 
against this molecular subtype. To identify BL-CL tumor cells, we classified breast 
cancer cell lines genomically by utilizing the intrinsic molecular subtyping of breast 
cancer, based on gene-expression profiles [1]. This chapter describes a step-wise 
process of drug screening crude fractions and isolating the active compounds to 
identify a novel therapeutic leads personalized against BL-CL. This study identified 
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a previously uncharacterized sulfated sterol, TLT, capable of inhibiting both AMPK 
and CHK, a targeting strategy that was also identified to be particularly effective 
against BL-CL. Furthermore, following the generation of a TLT sensitivity gene-
expression signature and the projection across a dataset of diverse human 
tumors, bladder cancer predicted to be as equally sensitive to TLT as breast 
cancer. Indeed, bladder cancer harbors frequent deregulation in the AMPK and 
CHK1 pathways. In summary, the results described in these chapters highlight the 
importance of the incorporation of cancer genomics and personalized medicine in 
cancer drug discovery as means to identify effective treatments against complex 
cancer phenotypes.
4.2  Personalized Medicine in Cancer Should Not  
Exclusively Depend on Mutations
The landscape of small molecule therapy in cancer has been revolutionized 
dramatically over the last decade. This coincided with a move from a one-size-
fits-all strategy that emphasized cytotoxic chemotherapy to a more personalized 
medicine approach that focuses on the identifying molecularly targeted drugs that 
exploit the particular genetic vulnerabilities of cancer cells [2]. Currently, the field of 
personalized medicine in cancer is strongly dependent on the identification of single 
gene modifications as predictive biomarkers of therapy response. This approach 
involves tailoring targeted therapeutics to particular aberrant modifications of 
single genes that include translocation, copy number increase and mutations [3]. 
The ABL inhibitor imatinib is widely regarded as the pioneer drug that validated 
the concept of designing a small molecule to treat a specified patient population 
[2]. Indeed, when imatinib was given to chronic myeloid leukaemia patients (in 
which the malignancy is driven by the BCR-ABL translocation), the recorded 
improvement in survival was dramatic [4,5]. Further success was observed with 
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the initial pioneering study linking the HER2 monoclonal antibody trastuzumab to 
breast tumors overexpressing HER2 [6,7]. Mutations haven taken center stage 
since then, with the observations that EGFR and ALK-MET inhibitors in NSCLC, 
and the BRAF inhibitor vemurafenib were particularly effective against tumors 
harboring mutations in those proteins [8-10]. Indeed, today we recognize that the 
successful use of targeted therapy in cancer is reliant on predictive biomarkers of 
response for the purposes of patient selection. As such, in the era of personalized 
cancer medicine, companion diagnostics have become crucial in tailoring the 
ideal therapeutic to a particular patient [3]. This is particularly the case for cancers 
that are driven by complex signaling pathways that are difficult to target, such 
as RAS-active NSCLC. Problems arise when trying to characterize RAS pathway 
activation based solely on the mutation status of the RAS protein. This is due to the 
fact that the presence of mutated RAS does not necessarily indicate an oncogenic 
addiction to the RAS pathway. Indeed, previous observations have shown that 
KRAS dependency is widely variable in KRAS mutant cancer cell lines. Therefore, 
cancer cells may harbor an activating mutation in RAS, but not necessarily be 
addicted and dependent on the continual signaling of the pathway [11]. This has 
been observed in cancer cells carrying an activating mutation in KRAS but still 
exhibiting low overall RAS pathway activation, an observation recorded in Chapter 
2 of this dissertation and by the work of others [12]. Furthermore, the lack of an 
activation mutation on RAS does not imply that the network is off as additional 
components of the network such as EGFR, PDGFR and IGFR that are upstream of 
RAS can be activated, leading to the initiation of RAS pathway signal transduction 
[13-17]. Thus, focusing on a single protein of a large network composed of many 
components might limit the ability to accurately reflect activity [18]. Indeed, this is 
observed in Chapter 2 where we identify a panel of KRAS wild-type cancer lines 
characterized by an activated RAS pathway through gene-expression profiling of 
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pathway activation. It will be critical in future clinical trials to identify those tumors 
that are RAS-active, independent of the mechanism of RAS activation. By using 
mutation analysis alone, one overlooks a large population of tumors that do not 
carry particular mutations yet harbor activated oncogenic pathways. Therefore, 
the benefit of a particular treatment is lost on a large population of patients. As 
an example, there are currently clinical trials recruiting patients for EGFR + MEK 
inhibitor combinations based solely on RAS mutation status. The results presented 
in Chapter 2 suggest that using mutation status as a biomarker for that treatment 
1) fails as a biomarker of response in NSCLC and 2) does not provide optimal 
selection of responsive patients by leaving out patients diagnosed with KRAS wild 
type NSCLC tumors with an active RAS pathway. Through a more comprehensive 
genomic characterization of patients with deregulated pathway independent of the 
mechanism of activation, it may be possible to optimize selection of patients for 
clinical trial inclusion. 
4.3  Identifying Compounds Effective Against Tumor  
Subpopulations
The ultimate goal of drug discovery in cancer is to eradicate malignant cells 
while minimizing adverse effects on normal cells. The main strategy to achieve this 
goal involves exploiting differences in the activity or expression of the molecular 
targets driving cancer-specific cellular phenotypes in cancer cells as compared to 
normal cells. However, this is complicated by the inherent genomic heterogeneity 
of cancer. This creates diversity in the molecular drivers among tumors and makes 
the treatment of cancer require a much larger repertoire of drugs than the majority 
of other diseases [19].   
Various drug discovery approaches have been used to build the 
armamentarium necessary to treat cancer, ranging from hypothesis-driven 
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screening (targeting identified oncogenic drivers such as EGFR or HER2), to 
phenotype screening (identifying drugs effective against cellular phenotypes 
without regard for mechanism). Given our growing understanding of the molecular 
characteristics and weaknesses of cancer, pursuing hypothesis-driven targeted 
therapies has been a scientifically and logically appealing method [19]. This is 
reflected by the current predominant use of that approach in the field of cancer drug 
discovery. However, this target-based discovery in oncology has witnessed many 
challenges and limitations. Despite the large number of targeted agents approved 
and in clinical development, there have been very few instances of “magic bullets,” 
where a single target drives the cancer phenotype, as exemplified by imatinib’s 
exquisite effectiveness against BCR–ABL-driven chronic myeloid leukaemia [20]. 
Often, the signaling mediators targeted are nodes in complex signaling networks in 
which redundancy, compensatory crosstalk and feedback loops tend to reduce the 
predicted impact of a single targeted inhibitor. This contributes to the high failure 
rate of targeted therapeutics owing to insufficient efficacy in clinical trials [21]. On 
the other hand, phenotypic screening in general avoids oversimplified reductionist 
assumptions regarding molecular targets and instead focuses on functional effects; 
compounds that are discovered in phenotypic assays may be more likely to show 
clinical efficacy [19,22] . Indeed, the goal of this dissertation is to identify therapeutic 
leads effective against particular complex cancer phenotypes first and foremost, 
and then identify their mechanism of action. Through this top-down approach, we 
are able to identify therapeutic leads, and the tumor subpopulation they are most 
effective against. This is particularly possible with the use of genomic classification 
of tumors, which allows the segregation of the heterogeneous cancers into groups 
with similar molecular characteristics. Indeed, we show this in Chapters 2 and 3 
where we classify a RAS-active phenotype from NSCLC, and the BL-CL phenotype 
in breast cancer. For both these molecular subpopulations, we identified effective 
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therapeutic leads tailored specifically against them. Clinically, the ideal patient 
population has theoretically been identified, and effective therapeutics described. 
Further work is necessary to validate the findings, as discussed in the next section 
of this chapter.
4.4  Future Directions
The incorporation of gene expression molecular classification of cancer 
makes up the cornerstone of the work described in this dissertation. The ultimate 
goal of such classification is the identification of treatments personalized against 
particular molecular subtypes. Chapter 2 describes the use of a RAS gene 
expression signature as a biomarker of pathway activity and classifier of RAS-
active NSCLC. Chapter 3 utilizes the gene expression signature classification 
system pioneered by Perou et al. to subtype breast cancer tumors based on 
molecular attributes [1,23]. This dissertation shows the successful implementation 
of such an approach in cancer drug discovery in a research setting; however, 
this method was not investigated as a possible clinic tool. One way to address 
this would be to obtain a panel of patient NSCLC samples and analyze them for 
RAS pathway activation using the same methodology described in Chapter 2. This 
would then be followed by concurrent treatment with EGFR and MEK inhibitors, 
for the purpose of correlating treatment effectiveness to RAS pathway activation in 
the context of patient tumors. A similar approach could be used for the observation 
recorded in Chapter 3 regarding BL-CL breast cancer sensitivity to TLT and AMPK/
CHK1 inhibitors. Patient breast cancer samples can be classified according to 
the intrinsic molecular subtypes patient breast cancer samples, and the BL-CL 
samples examined for TLT and AMPK/CHK1 inhibitor sensitivity. However, future 
work will still need to validate the in vitro cell culture findings in preclinical in vivo 
models of NSCLC and breast cancer. To validate the findings of Chapter 2 in a 
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mouse model, it would be necessary to use a model of lung cancer development 
that generates KRAS mutant and wild-type tumors. One such model would be 
the 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) lung carcinogenesis 
murine model. NNK reproducibly induces pulmonary adenocarcinomas in 
laboratory rodents through KRAS mutation or the activation of EGFR, AKT and 
MAPK pathways [24,25]. To validate the Chapter 3 findings, the EF1α-PyMT10C 
breast carcinogenesis mouse model could be used since it is able to generate both 
luminal and basal-like tumors in nearly equal ratios [26]. For both these models, 
tumors could be biopsied and analyzed for molecular classification. Treatment 
would follow, and the results analyzed for the observation of the same correlation 
between BL-CL and RAS-active NSCLC sensitivity to EGFR+MEK and TLT or 
AMPK/CHK1 inhibition, respectively. 
The challenges of incorporating gene expression profiling in the clinic have 
been mitigated by the recent advances and successes of incorporating microarray 
diagnostics. Indeed, gene-expression signatures have recently made their way 
into the clinical and commercial sectors, laying the ground for the introduction of 
future gene expression signatures into the clinic [27]. One example is the FDA-
approved microarray-based gene expression profiling signature Mammaprint®, 
which uses frozen archived tissue as source material or tissue core sampled 
on fresh specimens preserved in RNA later to score the low/high risk of tumor 
metastasis [27-29]. Therefore, the application of a gene-expression signature 
as a genomic biomarker of RAS pathway activation as described in Chapter 2 is 
both promising and feasible in the clinic. Overall, our results show the significant 
correlation between RAS pathway activity and response to EGFR+MEK inhibition, 
and the predictive power of our signature which is independent of other factors 
such as cancer subtype of mutations in key pathway components.  In the clinic, the 
RAS-gene expression signature could be used to assess RAS pathway activation 
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status in a patient’s tumor. If the tumor has high pathway activity, that patient may 
be a candidate to receive EGFR+MEK dual inhibition. Indeed, the clinical potential 
of our study is supported by the validation of our observed correlation of RAS 
pathway activation and EGFR+MEK dual inhibition using FDA-approved inhibitors 
trametinib and erlotinib [30,31].
 Furthermore, a practical application of classifying breast tumors based on 
their molecular subtypes has recently made its way into the clinic in the form of the 
FDA-approved PAM50 gene signature. This signature measures the expression 
levels of 50 genes in surgically resected breast tumors with the purpose of classifying 
them according to one of the four intrinsic subtypes (Luminal A, Luminal B, HER2-
enriched, and Basal-like) [32,33]. In addition to identifying a tumor’s intrinsic 
subtype, the PAM50 signature generates a personalized score estimating patient 
probability of cancer recurrence by weighting the molecular subtype correlations, 
a subset of proliferation genes, and tumor size. This signature uses multiplexed 
fluorescently-labeled probe pairs to measure gene expression in frozen or formalin-
fixed paraffin-embedded (FFPE) tissues [33]. The availability of this signature in 
the clinic makes it feasible to subtype breast cancer tumors molecularly, in order to 
identify Basal-like tumors and tailor effective treatments. 
The discovery and identification of TLT in Chapter 3 is an exciting finding. 
This sulfated sterol, isolated from the marine topsentia species sponge, exhibits 
preferential tumoricidal effectiveness against BL-CL breast cancer, in comparison 
to Luminal and HER2+ tumors.  Mechanistically, TLT was observed to inhibit both 
AMPK and CHK1 effectively. The importance of inhibiting AMPK and CHK1 in 
BL-CL breast cancer was validated by investigating the effects of AMPK, CHK1 
and AMPK1+CHK1 small molecule targeted inhibition on a panel of breast cancer 
cell lines. Twenty breast cancer cell lines were treated with dorsomorphin C, an 
AMPK inhibitor [34], Ly2603618, a CHK1 inhibitor in phase 2 clinical trials [35], 
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and the combination of both together. Results showed that treating BL-CL breast 
cancer with either treatment strategy is significantly more effective against the 
subtype than Luminal/HER2+ breast cancer. This validates the importance of the 
inhibitory effects of TLT on AMPK and CHK1 in BL-CL breast cancer, and suggests 
the potential use of AMPK or CHK1 inhibition as a treatment for BL-CL breast 
cancer. However, further work is required to strengthen these findings. Although 
dorsomorphin c is a potent AMPK inhibitor, this compound has been shown to 
have high affinity towards other proteins such as BMP and ALK [36]. Unfortunately, 
no exclusive inhibitor of AMPK exists currently. As such, future work will have to 
investigate the importance of AMPK signaling in BL-CL by knocking down AMPK 
using siRNA or shRNA. 
Clinically, there are no available AMPK inhibitors. However, the CHK1 
inhibitor used in the work described in Chapter 3, Ly2603618, is in phase 2 clinical 
trials and could be a treatment option in the near future. PAM50 molecular subtyping 
of patient tumors could be used to tailor CHK1 inhibitor therapy to those diagnosed 
with Basal breast cancers. Alternatively, CHK1 targeted therapy could be tailored 
to patients diagnosed with triple negative breast cancers, which frequently overlap 
with BL-CL breast cancers [37,38]. 
In conclusion, the work presented in this dissertation discusses the feasibility 
of incorporating cancer genomics in cancer drug discovery for the purpose of 
identifying personalized medicine treatment strategies. Particularly, this approach 
has been successful in identifying novel treatment options for two complex cancer 
phenotypes that have been difficult to treat and identify therapeutic leads for. The 
findings lay the foundation for future studies regarding the potential of EGFR+MEK 
co-inhibition as a treatment for RAS-active NSCLC, and TLT or AMPK/CHK1 
inhibition as a candidate therapy against BL-CL. 
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